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Abstract
Summary Guidance is provided in a European setting on
the assessment and treatment of postmenopausal women
with or at risk from osteoporosis.
Introduction The European Foundation for Osteoporosis
and Bone disease (subsequently the International Osteopo-
rosis Foundation) published guidelines for the diagnosis
and management of osteoporosis in 1997. This manuscript
updates these in a European setting.
Methods The following areas are reviewed: the role of bone
mineral density measurement for the diagnosis of osteoporo-
sis and assessment of fracture risk; general and pharmaco-
logical management of osteoporosis; monitoring of
treatment; assessment of fracture risk; case finding strategies;
investigation of patients; health economics of treatment.
Results and conclusions A platform is provided on which
specific guidelines can be developed for national use.
Keywords Bonemineraldensity.
Diagnosisofosteoporosis.Fractureriskassessment.
Healtheconomics.Treatmentofosteoporosis
Preamble 1997TheEuropeanFoundationforOsteoporosis
and Bone Disease (subsequently the International
Osteoporosis Foundation) published guidelines for the
diagnosis and management of osteoporosis [1]. Since then,
there have been significant advances in the field of
osteoporosis. These include the development of many new
techniques for measuring bone mineral, improved methods
of assessing fracture risk and new treatments that have been
shown to significantly reduce the risk of fractures at
vulnerable sites. Against this background, the Scientific
Advisory Board of the European Society for Clinical and
Economic Evaluation of Osteoporosis and Osteoarthritis
(ESCEO), in collaboration with the International
Osteoporosis Foundation, has recognised a need to revise
the original guidelines which are detailed below. The term
guideline is supplanted by the term guidance, to avoid any
prescriptive connotations since country or region specific
guidelines are now widely available. Rather, the guidance
can inform the development of new guidelines or the
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Introduction
Osteoporosis is defined as a systemic skeletal disease
characterised by low bone mass and microarchitectural
deterioration of bone tissue, with a consequent increase in
bone fragility and susceptibility to fracture [1]. Although
the diagnosis of the disease relies on the quantitative
assessment of bone mineral density (BMD), which is a
major determinant of bone strength, the clinical significance
of osteoporosis lies in the fractures that arise. In this
respect, there are some analogies with other multifactorial
chronic diseases. For example, hypertension is diagnosed
on the basis of blood pressure, whereas an important
clinical consequence of hypertension is stroke.
Common sites for osteoporotic fracture are the spine,
hip, distal forearm and proximal humerus. The remaining
lifetime probability in women at the menopause of a
fracture at any one of these sites exceeds that of breast
cancer (approximately 12%), and the likelihood of a
fracture at any of these sites is 40% or more in developed
countries (Table 1)[ 2], a figure close to the probability of
coronary heart disease. In the year 2000, there were
estimated to be 620,000 new fractures at the hip, 574,000
at the forearm, 250,000 at the proximal humerus and
620,000 clinical spine fractures in men and women aged
50 years or over in Europe. These fractures accounted for
34.8% of such fractures worldwide [3]. Osteoporotic
fractures also occur at many other sites including the
pelvis, ribs, and distal femur and tibia. Collectively, all
osteoporotic fractures account for 2.7 million fractures in
men and women in Europe at a direct cost of 36 billion
Euros [4].
Osteoporotic fractures are a major cause of morbidity in
the population. Hip fractures cause acute pain and loss of
function, and nearlyalways lead to hospitalisation. Recovery
is slow and rehabilitation is often incomplete, with many
patients permanently institutionalised in nursing homes.
Vertebral fractures maycauseacute painandloss offunction,
but may also occur without serious symptoms. Vertebral
fractures often recur, however, and the consequent disability
increases with the number of fractures. Distal radial fractures
also lead to acute pain and loss of function, but functional
recovery is usually good or excellent.
It is widely recognised that osteoporosis and the conse-
quent fractures are associated with increased mortality, with
the exception of forearm fractures [5]. In the case of hip
fracture, most deaths occur in the first 3–6 months
following the event, of which 20–30% is causally related
to the fracture event itself. The estimates of deaths from
Sweden that are causally related to hip fracture are
appreciable and suggest that more than 1% of all deaths
are due to hip fracture [6], somewhat higher than the
percentage of deaths attributed to pancreatic cancer and
somewhat lower than the percentage of deaths attributed to
breast cancer (Table 2).
A general approach to quantifying the burden of disease,
favoured by the WHO and World Bank, is to assess the
disability incurred by disease, including deaths due to the
disorder as well as the disability that arises in survivors [7].
The approach, based on disability and life-years lost
(DALYs), permits a comparison with other disease states.
Figures 1 and 2 show the burden in Europe compared with
that for other chronic diseases. Osteoporosis accounted for
more DALYs than rheumatoid arthritis, but fewer than
osteoarthritis. With regard to neoplastic diseases, the burden
of osteoporosis was greater than for all sites of cancer, with
the exception of lung cancers [3].
Table 1 Remaining lifetime probability (%) of common osteoporotic
fractures in Swedish men and women aged 50 years. (Reprinted from
[2], with kind permission from Springer Science + Business Media)
Site of fracture Women aged
50 years
Men aged
50 years
Hip 22.9 10.7
Distal forearm 20.8 4.6
Spine (clinical) 15.1 8.3
Proximal humerus 12.9 4.9
Any of the above 46.4 22.4
Table 2 Principal causes of death from selected diseases in Swedish
men and women in 1998. (Reprinted from [6], with permission from
Elsevier)
Men Women Total %
Acute myocardial infarction 7,113 5,335 12,448 13.3
Cardiovascular accident 4,411 6,069 10,480 11.2
Lung cancer 1,761 1,112 2,873 3.1
Prostate cancer 2,480 0 2,480 2.6
Chronic obstructive airways
disease
944 723 1,667 1.8
Diabetes 744 819 1,563 1.7
Breast cancer 11 1,549 1,560 1.7
Hip fracture 566 854 1,420 1.5
Pancreatic cancer 603 736 1,339 1.4
Suicide 880 349 1,229 1.3
Atrial fibrillation 413 687 1,091 1.2
Stomach cancer 489 334 823 0.9
Transport accidents 422 142 564 0.6
Smoke inhalation and fire 85 53 138 0.2
All deaths 46,840 46,788 93,628 100
400 Osteoporos Int (2008) 19:399–428The high societal and personal costs of osteoporosis pose
challenges to public health and physicians, particularly
since most patients with osteoporosis remain untreated. The
aims of this guidance are to stimulate a cohesive approach
to the management of osteoporosis in Europe. Although the
guidance is focussed on postmenopausal women, the same
general principles apply to men as well as women.
Bone mineral measurements and diagnosis
of osteoporosis
The objectives of bone mineral measurements are to
provide diagnostic criteria, prognostic information on the
probability of future fractures, and a baseline on which to
monitor the natural history of the treated or untreated
patient. BMD is the amount of bone mass per unit volume
(volumetric density), or per unit area (areal density), and
both can be measured in vivo by densitometric techniques.
Techniques to measure bone mineral
A wide variety of techniques is available to assess bone
mineral that are reviewed elsewhere [8–10]. The most
widely used are based on X-ray absorptiometry in bone,
particularly dual-energy X-ray absorptiometry (DXA) since
the absorption of X-rays is very sensitive to the calcium
content of the tissue of which bone is the most important
source. Other techniques include quantitative ultrasound
(QUS), quantitative computed tomography (QCT), both
applied to the appendicular skeleton and to the spine,
peripheral DXA, digital X-ray radiogrammetry, radiograph-
ic absorptiometry, and other radiographic techniques. Other
important determinants of bone strength for both cortical
and trabecular bone include macro- and microarchitecture.
X-ray-based technology is becoming available to estimate
these components of bone strength.
Dual-energy X-ray absorptiometry (DXA) is the most
widelyusedbonedensitometric technique.Itisversatile inthe
sense that it can be used to assess bone mineral content of the
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Osteoporos Int (2008) 19:399–428 401whole skeleton as well as of specific sites, including those
most vulnerable to fracture [8, 11, 12]. The term bone
mineral content describes the amount of mineral in the
specific bone site scanned. This can then be used to derive a
value for BMD by dividing the bone mineral content by the
area measured. This is, therefore, an areal density (g/cm
2)
rather than a true volumetric density (g/cm
3) since the scan is
two-dimensional. Areal BMD accounts for about two-thirds
of the variance of bone strength as determined in vitro on
isolated bones, such as the vertebral body or proximal femur.
Dual-energy X-ray absorptiometry can also be used to
visualise lateral images of the spine from T4 to L4 to detect
deformities of the vertebral bodies. Vertebral fracture
assessment (VFA) may improve fracture risk evaluation,
since many patients with vertebral fracture may not have a
BMD T-score classified as osteoporosis. This procedure
involves less radiation and is less expensive than a
conventional X-ray examination. VFA has a sensitivity
and specificity of about 90% for the detection of grade 2
and 3 fractures, according to the semiquantitative method of
Genant. Whereas whole body bone, fat and lean mass can
also be measured using DXA, these measurements are
useful for research, but do not assist in the routine diagnosis
or assessment of osteoporosis.
The performance characteristics of many measurement
techniques have been well documented [13–15]. For the
purpose of risk assessment and for diagnosis, the charac-
teristic of major importance is the ability of a technique to
predict fractures. This is traditionally expressed as the
increase in the relative risk of fracture per standard
deviation unit decrease in bone mineral measurement—
termed the gradient of risk.
There are significant differences in the performance of
different techniques at different skeletal sites. In addition,
the performance depends on the type of fracture that one
wishes to predict [14, 16]. For example, BMD assessments
by DXA to predict hip fracture are more predictive when
measurements are made at the hip rather than at the spine or
forearm (Table 3). For the prediction of hip fracture, the
gradient of risk provided by hip BMD is 2.6. In other
words, the fracture risk increases 2.6-fold for each SD
decrease in hip BMD. Thus, an individual with a Z-score of
−3 at the hip would have a 2.6
3 or greater than 15-fold
higher risk than an individual of the same age with a Z-
score of 0. Where the intention is to predict any
osteoporotic fracture, the commonly used techniques are
comparable: the risk of fracture increases approximately
1.5-fold for each standard deviation decrease in the
measurement. Thus, an individual with a measurement of
3 standard deviations below the average value for age
would have a 1.5
3 or greater than 3-fold higher risk than an
individual with an average BMD. Note that the risk of
fracture in individuals with an average BMD is lower than
the average fracture risk, since BMD is normally distributed
in the general population, whereas the risk of fracture
increases exponentially with decreasing BMD.
The widespread clinical use of DXA, particularly at the
proximal femur and lumbar spine (central DXA), arises
from many prospective studies that have documented a
strong gradient of risk for fracture prediction. For example,
a widely cited meta-analysis [14] indicated that the risk of
hip fracture increased 2.6-fold for each standard deviation
decrease in BMD at the femoral neck. The gradient of risk
is even higher in women at, or just after the menopause
[17]. These gradients of risk are higher than those derived
using many other techniques, and the use of central DXA
predicts other types of fracture with as high a gradient of
risk as other competing techniques. The vast amount of
information available for central DXA has meant that it
has now become the reference standard. The adoption of
DXA as a reference standard provides a platform on which
the performance characteristics of less well established
methodologies can be compared.
The performance characteristics of ultrasound are simi-
lar. Most studies suggest that measurements of broadband
ultrasound attenuation (BUA) or speed of sound (SoS) at
the heel are associated with a 1.5- to 2-fold increase in risk
for each standard deviation decrease in BMD [15].
Comparative studies indicate that these gradients of risk
are very similar to those provided by peripheral assessment
of BMD at appendicular sites by absorptiometric techniques
to predict any osteoporotic fracture [14].
Diagnostic thresholds
The following four general descriptive categories are given
below for adult men and women using measurements of
DXA at the femoral neck [18, 19].
Table 3 Age-adjusted increase in risk of fracture (with 95% confidence interval) in women for every 1 SD decrease in bone mineral density
(BMD; by absorptiometry) below the mean value for age. (Amended with permission from the BMJ Publishing Group [14])
Site of measurement Forearm fracture Hip fracture Vertebral fracture All fractures
Distal radius 1.7 (1.4–2.0) 1.8 (1.4–2.2) 1.7 (1.4–2.1) 1.4 (1.3–1.6)
Femoral neck 1.4 (1.4–1.6) 2.6 (2.0–3.5) 1.8 (1.1–2.7) 1.6 (1.4–1.8)
Lumbar spine 1.5 (1.3–1.8) 1.6 (1.2–2.2) 2.3 (1.9–2.8) 1.5 (1.4–1.7)
402 Osteoporos Int (2008) 19:399–4281. Normal: a value for BMD that is higher than 1 standard
deviation below the young adult female reference mean
(T-score greater than or equal to −1 SD).
2. Low bone mass (osteopenia): a value for BMD more
than 1 standard deviation below the young female adult
mean, but less than2.5 SDbelow thisvalue(T-score <−1
and >−2.5 SD).
3. Osteoporosis: a value for BMD 2.5 SD or more below
the young female adult mean (T-score less than or equal
to −2.5 SD).
4. Severe osteoporosis (established osteoporosis): a value
for BMD 2.5 SD or more below the young female adult
mean in the presence of 1 or more fragility fractures.
The recommended reference range is the NHANES III
reference database for femoral neck measurements in
women aged 20–29 years [20, 21], as previously recom-
mended by the International Osteoporosis Foundation [22].
These diagnostic criteria for osteoporosis are similar to
those previously proposed by the World Health Organiza-
tion in 1994 [13, 23], but differ by specifying a reference
site (the femoral neck), providing a young normal reference
range, and by accommodating diagnostic criteria for men.
The original 1994 WHO criteria provided for diagnosis
of osteoporosis at the hip, lumbar spine or forearm. Data
arising with the development of new measurement tech-
niques applied to many different skeletal sites indicate that
the same T-score derived from different sites and techniques
yield quite different information on fracture risk The inter-
site correlations, though of statistical significance, are
inadequate for predictive purposes. These considerations
have led to the adoption of a reference site [22]. This does
not preclude the use of other sites and technologies in
clinical practice, though it should be recognised that the
information derived from the T-score will differ from that
provided by BMD at the femoral neck.
Diagnostic thresholds differ from intervention thresholds
for several reasons. First, the fracture risk varies markedly
in different populations. For example, in women with a
T-score of −2.5 SD, the probability of hip fracture is 5 times
greater at the age of 80 years than at the age of 50 years.
Other factors that determine intervention thresholds include
the presence of clinical risk factors, and high indices of
bone turnover. Intervention thresholds will also be deter-
mined in part by the cost and benefits of treatment.
Prevalence of osteoporosis
The prevalence of osteoporosis in Sweden using the WHO
criteria is shown for Swedish men and women in Table 4
[24]. Approximately 6% of men and 21% of women aged
50–84 years are classified as having osteoporosis. The
prevalence of osteoporosis in men over the age of 50 years
is 3 times less frequent than in women—comparable to the
difference in lifetime risk of an osteoporotic fracture in men
and women.
The prevalence of osteoporosis utilising either the total
hip or the femoral neck is rather similar in women,
suggesting that this site could eventually supplant the use
of femoral neck BMD when adequate meta-analyses have
delineated the performance of total hip BMD to estimate
fracture risk.
Measurement of multiple skeletal sites
A number of guidelines favour the concurrent use of BMD
at the proximal femur and at the lumbar spine for patient
assessment. Patients are defined as having osteoporosis on
the basis of the lower of two T-scores. For example, the
International Society for Clinical Densitometry recom-
mends that patients who have a BMD test receive scans
of both the lumbar spine and hip [25, 26]. Patients are
characterised as having osteoporosis where the T-score is
−2.5 SD or less at the spine, femoral neck or total hip. The
prediction of fracture is, however, not improved by the use
of multiple sites [27–29]. Selection of patients on the basis
of a minimum value from 2 or more tests will, however,
increase the number of patients selected. The same result
can be achieved by less stringent criteria for the definition
of osteoporosis, by defining osteoporosis, for example, as a
T-score of ≤−2.0 SD rather than ≤−2.5 SD. This would
undermine, however, the value of a single diagnostic
threshold.
Osteopenia
It is recommended that diagnostic criteria be reserved for
osteoporosis and that osteopenia should not be considered
to be a disease category. Provision is still, however, made
Table 4 Prevalence of osteoporosis at the age intervals shown in
Sweden using female-derived reference ranges at the femoral neck.
(Reprinted from [24], with permission from Elsevier)
Men Women
Age range
(years)
%o f
population
Number
affected (000)
%o f
population
Number
affected (000)
50–54 2.5 7.0 6.3 17.0
55–59 3.5 7.6 9.6 21.1
60–64 5.8 11.4 14.3 30.0
65–69 7.4 14.2 20.2 43.7
70–74 7.8 14.6 27.9 63.0
75–79 10.3 13.7 37.5 68.3
80–84 16.6 14.7 47.2 67.8
50–80 6.3 83.2 21.2 310.9
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descriptive purposes for the epidemiology of osteoporosis
rather than as a diagnostic criterion. Also, the identification
of osteopenia will capture the majority of individuals who
will develop osteoporosis in the next 10 years.
Limitations
There are a number of limitations in the general application
of DXA for diagnosis that should be recognised [30, 31].
The presence of osteomalacia, a complication of poor
nutrition in the elderly, will underestimate total bone mass
because of decreased mineralisation of bone. Osteoarthrosis
or osteoarthritis at the spine or hip are common in the
elderly, and contribute to the density measurement, but not
necessarily to skeletal strength. Heterogeneity of density
due to osteoarthrosis, previous fracture or scoliosis can
often be detected on the scan and in some cases excluded
from the analysis. Some of these problems can be overcome
with adequately trained staff and rigorous quality control.
As mentioned, the image is two dimensional and therefore
provides an areal BMD rather than a volumetric BMD. The
computation of BMD is sensitive to changes in bone size.
For example, areal bone density will overestimate volu-
metric bone density in individuals with large bones. In
adults, this error is fortuitously beneficial since larger bones
in general have higher strength. Thus, this “error” may
improve fracture prediction in adults.
General management
Mobility and falls
Immobilisation is a very important cause of bone loss.
Immobilised patients may lose as much bone in a week
when confined to bed as they would otherwise lose in a
year. For this reason immobility should wherever possible
be avoided. The amount of weight-bearing exercise that is
optimal for skeletal health in patients with osteoporosis is
not known, but exercise forms an integral component of
management [32]. Physiotherapy is an important compo-
nent of rehabilitation after fracture. At all times, increased
strength may prevent falls by improving confidence and
coordination as well as maintaining bone mass by stimu-
lating bone formation and by decreasing bone resorption.
Such measures can be coupled with a programme to
reduce the likelihood of falls in those at high risk.
Risk factors for falling are shown in Table 5 [33].
Modifiable factors such as the correcting decreased visual
acuity, reducing consumption of medication that alters
alertness and balance, and improvement of the home
environment (slippery floors, obstacles, insufficient light-
ing, handrails) are important measures aimed at preventing
falls. Although large trials have shown that it is possible to
reduce falls [34, 35], randomised studies have not shown
any significant decrease in fracture risk. Some randomised
trials have shown that wearing hip protectors can
markedly reduce hip fracture risk, particularly in the
elderly living in nursing homes. A recent meta-analysis
of well-conducted randomised controlled trials has, how-
ever, cast some doubt on the antifracture efficacy of this
preventive measure [36–38].
Nutrition
There is a high prevalence of calcium, protein and vitamin
D insufficiency in the elderly. Vitamin D supplements can
reduce the risk of falling provided the daily dose of vitamin
D is greater than 700 IU [39]. Whereas a gradual decline in
caloric intake with age can be considered as an appropriate
adjustment to the progressive reduction in energy expendi-
ture, the parallel reduction in protein intake may be
detrimental for maintaining the integrity and function of
several organs or systems, including skeletal muscle and
bone. Calcium and vitamin D supplements decrease
secondary hyperparathyroidism and reduce the risk of
proximal femur fracture, particularly in the elderly living
in nursing homes. Intakes of at least 1,000 mg/day of
calcium, 800 IU of vitamin D and of 1 g/kg body weight of
protein can be recommended in the general management
of patients with osteoporosis [40].
Sufficient protein intakes are necessary to maintain the
function of the musculoskeletal system, but they also
decrease the complications that occur after an osteoporotic
fracture. Correction of poor protein nutrition in patients
with a recent hip fracture has been shown to improve the
subsequent clinical course by significantly lowering the rate
of complications, such as bedsores, severe anaemia, and
intercurrent lung or renal infection. The duration of hospital
stay of elderly patients with hip fracture can thus be
shortened. [41].
Table 5 Risk factors associated with falls. (Adapted from [33], with
permission from Elsevier)
Number Risk factor
1. Impaired mobility, disability
2. Impaired gait and balance
3. Neuromuscular or musculoskeletal disorders
4. Age
5. Impaired vision
6. Neurological, heart disorders
7. History of falls
8. Medication
9. Cognitive impairment
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The most commonly used agents in Europe are raloxifene, the
bisphosphonates alendronate, ibandronate and risedronate,
agents derived from parathyroid hormone and strontium
ranelate. Until recently, hormone replacement treatment was
also widely used. They have all been shown to reduce the risk
ofvertebralfracture.Somehavebeenshowntoalsoreducethe
risk of non-vertebral fractures, in some cases specifically
fractures at the hip (Table 6)[ 42, 43].
Selective estrogen-receptor modulators
Selective estrogen-receptor modulators (SERMs) are non-
steroidal agents that bind to the oestrogen receptor and act
as oestrogen agonists or antagonists, depending on the
target tissue. The concept of SERMs was triggered by the
observation that tamoxifen, which is an oestrogen antag-
onist in breast tissue, is a partial agonist on bone, reducing
the rate of bone loss in postmenopausal women. Ralox-
ifene is the only SERM available for the prevention and
treatment of postmenopausal osteoporosis, but several
others are in clinical development. Raloxifene prevents
bone loss [44] and reduces the risk of vertebral fractures
by 30–50% in postmenopausal women with low bone
mass, and with osteoporosis with or without prior
vertebral fractures as shown in the MORE trial [45].
There was no significant reduction of non-vertebral
fractures. In women with severe vertebral fractures at
baseline (i.e. at highest risk of subsequent fractures) a post
hoc analysis showed a significant reduction of non-
vertebral fractures [46]. In the MORE study and its
placebo-controlled 4-year follow-up (CORE), the only
severe (but rare) adverse event was an increase in deep
venous thromboembolism. There was a significant and
sustained significant decrease in the risk of invasive breast
cancer (by about 60%) [47], which has been subsequently
confirmed in two other large cohorts, including the STAR
study, which showed a similar breast cancer rate with
raloxifene and tamoxifen in high-risk populations [48].
The RUTH study, performed in postmenopausal women at
high risk of cardiovascular disease [49]s h o w e dt h a t
raloxifene had no effect on cardiovascular death, and on
the incidence of coronary heart disease and stroke, [50]. In
summary, the overall risk benefit ratio of raloxifene is
favourable and the drug is approved widely for the
prevention and treatment of postmenopausal osteoporosis.
Bisphosphonates
Bisphosphonates are stable analogues of pyrophosphate
characterised by a P-C-P bond. Avariety of bisphosphonates
has been synthesised, the potency of which depends on the
length and structure of the side chain. Bisphosphonates have
a strong affinity for bone apatite, both in vitro and in vivo,
which is the basis for their clinical use. They are potent
inhibitors of bone resorption and produce their effect by
reducing the recruitment and activity of osteoclasts and
increasing their apoptosis. The potency of bisphosphonates
in inhibiting bone resorption varies greatly from compound
to compound and ranges 10,000-fold in vitro, so that the
doses used clinically also vary. The mechanism of action on
osteoclasts includes inhibition of the proton vacuolar
adenosine triphosphatase (ATPase) and alteration of the
cytoskeleton and the ruffled border. Aminobisphosphonates
also inhibit several steps of the mevalonate pathway, thereby
modifying the isoprenylation of guanosine triphosphate
binding proteins.
Table 6 Antifracture efficacy of the most frequently used treatments for postmenopausal osteoporosis when given with calcium and vitamin D, as
derived from randomised controlled trials. (Updated from [42, 43])
Effect on vertebral fracture risk Effect on non-vertebral fracture risk
Osteoporosis Established osteoporosis
a Osteoporosis Established osteoporosis
a
Alendronate + + NA + (including hip)
Risedronate + + NA + (including hip)
Ibandronate NA + NA +
b
Zoledronic acid + + NA NA (+)
c
HRT + + + +
Raloxifene + + NA NA
Teriparatide and PTH NA + NA +
Strontium ranelate + + +(including hip) + (including hip)
NA: no evidence available
+: effective drug
aWomen with a prior vertebral fracture
bIn subsets of patients only (post-hoc analysis)
cMixed group of patients with or without prevalent vertebral fractures
Osteoporos Int (2008) 19:399–428 405Oral bioavailability of bisphosphonates is low, between
1 and 3% of the dose ingested, and is impaired by food,
calcium, iron, coffee, tea and orange juice. Bisphosphonates
are quickly cleared from plasma, about 50% being
deposited in bone and the remainder excreted in urine.
Their half-life in bone is very prolonged.
Alendronate 70 mg once weekly and risedronate 35 mg
once weekly are the most commonly used bisphospho-
nates worldwide. In the FIT study, alendronate was shown
to reduce the incidence of vertebral, wrist and hip
fractures by approximately half in women with prevalent
vertebral fractures [51–53]. In women without prevalent
vertebral fractures, there was no significant decrease in
clinical fractures in the overall population, but the reduction
was significant in the one-third of patients who had a
baseline hip BMD T-score lower than −2.5 SD [54].
Risedronate has been shown in women with prevalent
vertebral fractures to reduce the incidence of vertebral and
non-vertebral fractures by 40–50% and 30–36% respec-
tively [55, 56]. In a large population of elderly women,
risedronate decreased significantly the risk of hip fractures
(by 30%), an effect that was greater in osteoporotic women
aged 70–79 years (−40%), and not significant in women
over the age of 80 years without evidence of osteoporosis
[57].
Ibandronate given daily (2.5 mg) reduces the risk of
vertebral fractures by 50–60%, whereas an effect on non-
vertebral fractures was only demonstrated in a post hoc
analysis of women with a baseline of BMD T-score below −3
SD [58, 59]. Bridging studies have shown that oral
ibandronate 150 mg once monthly is equivalent or superior
to daily ibandronate in increasing BMD and decreasing
biochemical markers of bone turnover, giving rise to its
approval for the treatment of postmenopausal osteoporosis
[60]. Similarly, bridging studies comparing intermittent intra-
venous ibandronate with daily oral treatment has lead to the
approval of intravenous ibandronate (3 mg) every 3 months
for the treatment of postmenopausal osteoporosis [61].
Based on the result of a phase II study [62], a large phase
III trial has been recently completed in over 7,500
postmenopausal osteoporotic patients assessing the efficacy
of yearly infusion of zoledronate 5 mg over 3 years.
Compared with the placebo group, zoledronate was found
to reduce the incidence of vertebral fractures by 70% and
that of hip fractures by 40% [63], and is now available for
the treatment of postmenopausal osteoporosis. Intravenous
zoledronate has also been shown to decrease the risk of
fracture and attendant mortality when given shortly after a
first hip fracture [64].
The overallsafetyprofile ofbisphosphonates isfavourable.
Oralbisphosphonatesareassociatedwithmildgastrointestinal
disturbances, and some aminobisphosphonates (alendronate
and pamidronate) can rarely cause oesophagitis. Intravenous
aminobisphosphonates can induce a transient acute phase
reaction with fever, bone and muscle pain that ameliorates or
disappears after subsequent courses. Osteonecrosis of the jaw
has been described in cancer patients receiving high doses of
intravenous pamidronate or zoledronate. The incidence in
osteoporotic patients treated with oral and intravenous
bisphosphonates appears to be extremely low (in the order
of 1/100,000 cases), and its causal relationship with
bisphosphonate therapy has not been established.
Peptides of the parathyroid hormone family
The continuous endogenous production of parathyroid
hormone (PTH), as seen in primary or secondary hyperpara-
thyroidism, or its exogenous administration, can lead to
deleterious consequences for the skeleton, particularly on
cortical bone. However, intermittent administration of PTH
(e.g. with daily subcutaneous injections) results in an increase
in the number and activity of osteoblasts, leading to an
increase in bone mass and in an improvement in skeletal
architecture at both cancellous and cortical skeletal sites.
The intact molecule (amino acids 1–84) and the 1–34
N-terminal fragment (teriparatide) are used for the manage-
ment of osteoporosis. Based on their respective molecular
weights, the equivalent dose of the teriparatide, relative to
the 1–84 molecule is 40% (i.e. 20 and 40 μg of teriparatide
are equivalent to 50 and 100 μgo f1 –84 PTH respectively).
Treatment with either agent has been shown to reduce
significantly the risk of vertebral fractures, whereas
teriparatide has been shown to have an effect also on
non-vertebral fractures. The recommended doses are
respectively 20 μg of teriparatide and 100 μg of PTH
(1–84) daily, given as a subcutaneous injection [65, 66].
Treatment with PTH has been studied when given for 18
to 24 months and beneficial effects on non-vertebral
fractures with teriparatide have been shown to persist for
up to 30 months after stopping teriparatide. [67].
The most common reported adverse events in patients
treated with PTH or teriparatide are nausea, pain in the
limbs, headache and dizziness. In normocalcaemic patients,
slight and transient elevations of serum calcium concen-
trations have been observed following the injection of PTH
or teriparatide. Serum calcium concentrations reach a
maximum between 4 and 6 h and return to baseline 16–
24 h after each dose. The change is small and routine
monitoring of serum calcium during therapy is not required.
PTH and teriparatide may cause small increases in urine
calcium excretion, but the incidence of hypercalciuria does
not differ from that in placebo-treated patients. However,
these agents should be used with caution in patients with
active or recent urolithiasis because of their potential to
exacerbate the disorder. Isolated episodes of transient
orthostatic hypotension are also reported. They typically
406 Osteoporos Int (2008) 19:399–428resolve within minutes to a few hours, and do not preclude
continued treatment.
The use of peptides of the PTH family is contra-indicated
in conditions characterised by abnormally increased bone
turnover (e.g. pre-existing hypercalcaemia, metabolic bone
diseases other than primary osteoporosis, including hyper-
parathyroidism and Paget’s disease of the bone, unexplained
elevation of alkaline phosphatase, prior external beam or
implant radiation therapy to the skeleton or in patients with
skeletal malignancies or bone metastasis). Severe renal
impairment is also a contra-indication. Studies in rats have
indicated an increased incidence of osteosarcoma, with long-
term administration of very high doses of teriparatide from
the time of weaning. These findings appear to have not been
considered relevant for patients treated with very much
smaller doses of teriparatide.
Strontium ranelate
Strontium ranelate is a recently registered agent that is
marketed for the treatment of postmenopausal osteoporo-
sis, to reduce the risk of vertebral and hip fractures. There
is some evidence that strontium ranelate both inhibits
bone resorption and stimulates bone formation, suggesting
that the agent may uncouple the bone remodelling process
when used in the treatment of osteoporosis. Studies
conducted for up to 5 years have shown the fracture
efficacy of strontium ranelate, at spinal and non-vertebral
sites, in a wide range of patients, from osteopenia
sufferers to women over the age of 80 years, including
osteoporotic patients with or without a prior vertebral
fracture. Reduction in hip fracture rates has also been
shown in women over the age of 74 years with low bone
density at the femoral neck. The decrease in fracture rates
observed with strontium ranelate is of similar magnitude
to that described for oral bisphosphonates [68, 69].
The recommended daily dose is one 2-g sachet once
daily by mouth. The absorption of strontium ranelate is
reduced by food, milk and its derivative products and the
drug should be administered, therefore, between meals.
Ideally, it should be taken at bed-time, preferably at least
two hours after eating. No dosage adjustment is required in
relation to age or in patients with mild to moderate renal
impairment (creatinine clearance 30–70 ml/min). Strontium
ranelate is not recommended for patients with severe renal
impairment (creatinine clearance below 30 ml/min).
Adverse events observed with strontium ranelate are
usually mild and transient. The most common adverse
events are nausea and diarrhoea, which are generally
reported at the beginning of treatment and usually disappear
after the third month of treatment).
An increase in the incidence of venous thromboembolism
(VTE; relative risk 1.42; CI = 1.02, 1.98) has been reported
when pooling all phase III studies in osteoporosis. A causal
relationship between VTE and the use of strontium ranelate
has not been established and regulatory authorities have not
considered a history of VTE as a contra-indication to the use
of strontium ranelate. However, strontium ranelate should be
used with caution in patients at increased risk of VTE,
including those with a past history. When treating patients
with an increased risk of developing risk of VTE, particular
attention should be given to possible signs and symptoms of
VTE and appropriate preventive measures taken.
The effects of the major pharmacological interventions
on vertebral and hip fracture risk are summarised in Table 7.
Combination and sequential treatments
These treatment regimens include the concomitant or
sequential use of compounds sharing the same mode of
action (e.g. two or more inhibitors of bone resorption) or
agents with differing activities (e.g. an inhibitor of
resorption plus an anabolic agent). The hope that synergies
might be found by combination treatments has not yet been
realised.
Most of the current findings suggest that the combina-
tion of two inhibitors of bone resorption results in a more
pronounced decrease in bone resorption that induces a
greater increase in BMD than either agent alone. Whether
this results in a better effect on fracture risk has not been
adequately addressed. None of the published trials has been
designed and powered to detect differences in fracture rates
between treatment groups [70].
If low doses of hormone replacement treatment (HRT)
are used for a limited period of time for the management of
climacteric symptoms, concomitant use of bisphosphonates
may provide an appropriate reduction in bone turnover that
may not be achieved with low doses of HRT alone. The
combination of SERMs and bisphosphonates does not
appear to be deleterious for bone, but the use of the
combination remains questionable in terms of fracture
reduction and from a pharmaco-economic perspective.
Patients pre-treated with inhibitors of bone resorption,
who have not achieved a full therapeutic response, are good
candidates for treatment with anabolic agents. The increase
in bone turnover that follows the introduction of teripara-
tide in patients treated with an anti-resorptive agent is
similar to that observed in treatment-naïve patients as is
the pattern of response in BMD, with the exception of a
6-month delay in the increase in spinal and hip BMD in
patients previously exposed to alendronate [71].
An important question is whether the combination of an
anti-resorptive agent and an anabolic drug, such as PTH,
would provide a therapeutic advantage by exploiting the
different mechanisms of action on bone, and thereby
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used for postmenopausal osteoporosis when given with calcium and vitamin D, as derived from randomised controlled trials
Intervention Study Entry criteria Mean age
(years)
Number of
patients
randomised
Fracture
incidence
(percentage over
3 years)
d
RR (95%CI)
Placebo Drug
Vertebral fracture (high-risk population)
Alendronate 5–10 mg [51] Vertebral fractures, BMD ≤ 0.68 g/m
2 71 2,027 15.0 8.0 0.53 (0.41–0.68)
Risedronate 5 mg [55] 2 vertebral fractures or 1 vertebral
fracture and T-score ≤−2.0
69 2,458 16.3 11.3 0.59 (0.43–0.82)
Risedronate 5 mg [56] 2 or more vertebral fractures—no
BMD entry criteria
71 1,226 29.0 18.0 0.51 (0.36–0.73)
Raloxifene 60 mg [45] Vertebral fractures—no BMD
entry criteria
66 7,705 21.2 14.7 0.70 (0.60–0.90)
Teriparatide 20 μg
a [65] Vertebral fractures and FN or LS
T-score ≤−1 if less than 2 moderate
fractures
69 1,637 14.0 5.0 0.35 (0.22–0.55)
Ibandronate 2.5 mg [58] Vertebral fractures and LS −5<
T-score ≤−2.0
69 2,946 9.6 4.7 0.38 (0.25–0.59)
Ibandronate 20 mg [59] Vertebral fractures and LS –5<
T-score ≤−2.0
70 708 9.6 4.9 0.50 (0.34–0.74)
Strontium ranelate 2 g [68] Vertebral fractures, LS BMD≤
0.840 g/m
2
69 1,649 32.8 20.9 0.59 (0.48–0.73)
Zoledronic acid 5 mg [63] FN T score ≤− 2.5, ± vertebral fracture,
or T-score ≤− 1.5 and 2+ mild or 1
moderate vertebral fracture
73 7,765 10.9 3.3 0.30 (0.24–0.38)
Vertebral fracture (low-risk population)
Alendronate 5–10 mg
b [54] FN T-score ≤−2 68 4,432 3.8 2.1 0.56 (0.39–0.80)
Alendronate 5–10 mg
b [54] Subgroup of women, T-score <2.5 NA 1,631 4.0 2.0 0.50 (0.31–0.82)
Raloxifene 60 mg [45] FN or LS T-score ≤−2.5, ±
vertebral fractures
66 7,705 4.5 2.3 0.50 (0.40–0.80)
Hip fracture
Alendronate 5–10 mg [51] Vertebral fractures with
BMD≤0.68 g/m
2
71 2,027 2.2 1.1 0.49 (0.23–0.99)
Alendronate 5–10 mg
b [54] FN T-score ≤−2
c 68 4,432 0.8 0.7 0.79 (0.43–1.44)
Alendronate 5–10 mg
b [54] FN T-score ≤−2.5
c
(subgroup analysis)
NA 1,631 1.6 0.7 0.44 (0.18–1.97)
Risedronate 2.5
and 5 mg
[57] T-score <−3
c or <−2
c and ≥1
non-skeletal risk factor for hip
fracture (subgroup analysis osteoporotic
patients 70–79 years)
77 9,331 3.2 1.9 0.60 (0.40–0.90)
Raloxifene 60 and
120 mg
[45]F N o r L S T –score ≤−2.5, ±
vertebral fractures
66 7,705 0.7 0.8 1.10 (0.60–1.90)
Strontium ranelate 2 g [69] Osteoporosis (T-score < −2.5) with
or without prior fracture
77 4,932 3.4 2.9 0.85 (0.61–1.19)
Strontium ranelate 2 g [69] Age ≥ 74 with T-score ≤−2.4
c
(subgroup analysis)
80 1,977 6.4 4.3 0.64 (0.412–
0.997)
Zoledronic acid 5 mg [63] FN T score ≤− 2.5 or less, ± vertebral
fracture, or T-score ≤− 1.5 and 2+
mild or 1 moderate vertebral fracture
73 7,765 1.4 2.5 0.59 (0.42–0.83)
FN: femoral neck; LS: lumbar spine: NA: not available
a20-month study
b4.2-year study
cBMD adjusted to NHANES population
dExcept where indicated in column 1
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patients to daily treatment with PTH (1–84, 100 μg/day)
alone, alendronate (10 mg/day) alone, or both, volumetric
density of the trabecular bone at the spine increased
substantially in all groups, but the increase in the PTH
alone group was about twice that found in either of the
other groups. Thus, there was no evidence of synergy
between PTH and alendronate [72]. The authors considered
that the changes in the volumetric density of trabecular
bone, the cortical volume at the hip (significantly increased
in the PTH group, but not in the other treatment groups)
suggest that the concurrent use of alendronate may reduce
the anabolic effects of PTH. A similar conclusion was
reached in men, in that alendronate impaired the effects of
PTH to increase BMD at the lumbar spine and femoral
neck. These results suggest that, if therapy with PTH is
contemplated, it should be used alone and not with
alendronate [73]. Whether this can be extrapolated to
other bisphosphonates or other anti-resorptive agents
remains unclear. Notwithstanding, some preliminary studies
suggest that SERMs (raloxifene) or other bisphosphonates
(risedronate) may not reduce the anabolic effects of PTH to
t h es a m ee x t e n t[ 74]. The apparent absence of the
synergistic effect of PTH and alendronate should not
obscure the potential benefit of using an inhibitor of
resorption after treatment with PTH. Indeed, there are data
that suggest that the administration of an inhibitor of
resorption (bisphosphonate or SERM) after treatment with
PTH maintains or even potentiates the skeletal benefit
observed during PTH treatment [75].
Other pharmacological interventions
Calcitonin
Calcitonin is an endogenous polypeptide hormone that
inhibits osteoclastic bone resorption [76]. Salmon calcitonin
is approximately 40–50 times more potent than human
calcitonin, and the majority of clinical trials have been
performed with salmon calcitonin [77]. For clinical use it
can be administered either by injection or nasal application,
which provides a biological activity of 25–50% compared
with the injectable formulation (200 IU nasal calcitonin
would be equivalent to 50 IU of the injectable formulation).
Calcitonin modestly increases BMD at the lumbar spine
and forearm [53, 78]. Calcitonin likely reduces the risk of
vertebral fracture; however, the magnitude of the impact on
these fractures remains questionable [53, 79]. An effect on
non-vertebral fractures remains equivocal [79, 80]. In
addition, calcitonin may have an analgesic effect in women
with acute vertebral fracture, which appears to be indepen-
dent of its effect on osteoclastic resorption [77].
In conclusion, the drawbacks of repeated injections and
the high costs of the nasal formulation preclude the long-
term use of calcitonin as a first-line treatment of osteopo-
rosis. Analgesic properties may, however, be an interesting
option for acute pain following a spinal fracture.
Hormone replacement therapy
Oestrogens reduce the accelerated bone turnover induced
by the menopause, and prevent bone loss at all skeletal sites
regardless of age and duration of therapy. Results from
observational studies and randomised placebo-controlled
trials have shown that oestrogens decrease the risk of
vertebral and non-vertebral fractures (including hip frac-
ture) by about 30%, regardless of baseline BMD [42, 81,
82]. When hormone replacement therapy (HRT) is stopped,
bone loss resumes at the same rate as after the menopause,
but fracture protection may persist arguably for several
years [83, 84].
The Women’s Health Initiative (WHI) suggests, how-
ever, that the long-term risks of HRT outweigh the benefits.
In this large cohort of postmenopausal women in their
60s, the combined use of conjugated oestrogen and
medroxyprogesterone acetate was associated with a 30%
increased risk of coronary heart disease (CHD) and breast
cancer, and with a 40% increase in stroke [85–87]. There
was also a slight increase in the risk of dementia [88], and
no clinically meaningful effect on health-related quality of
life such as sleep disturbance or vasomotor symptoms [89].
In a subsequent analysis, the increase in breast cancer risk
was much less in women not previously exposed to HRT
[87]. In hysterectomised women receiving conjugated
oestrogen alone, there was also a significant increase in
stroke, but not in CHD and breast cancer, suggesting a
deleterious effect of medroxyprogesterone acetate [90].
Whether the benefits of HRT would outweigh the risks
with other oestrogen and progestin and in younger
postmenopausal women is debated, but so far there has
been no placebo-controlled study showing the long-term
safety of such alternatives. In most countries, HRT is only
recommended for climacteric symptoms, at a dose as small
as possible and for a limited period of time. Thus, HRT is
no longer recommended as a first-line treatment for the
prevention and treatment of osteoporosis.
Etidronate
Etidronate is a weak bisphosphonate that has been shown
to reduce vertebral fractures over 2 years, but not
subsequently, with no significant effect on non-vertebral
fractures [91]. Thus, etidronate is not recommended as a
first-line therapy for osteoporosis in most European
countries.
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Alfacalcidol is a synthetic analogue of the vitamin D
metabolite calcitriol (1,25-dihydroxyvitamin D3) and it is
metabolised to calcitriol by its 25-hydroxylation in the liver.
It is somewhat less potent than calcitriol. Both alfacalcidol
and calcitriol are used in some countries for the treatment of
osteoporosis. Several but not all studies show decreases in
vertebral fracture risk [92–94]. The effects on BMD have
been less extensively studied.
A few reports have suggested that alfacalcidol and
calcitriol exert a direct action on muscle strength and
decrease the likelihood of falling in elderly subjects [95].
The major problem with the use of the vitamin D
derivatives is the risk of hypercalcaemia and hypercalciuria.
Adverse effects of prolonged hypercalcaemia include
impairment of renal function and nephrocalcinosis. The
narrow therapeutic window demands the frequent surveil-
lance of serum and possibly urine calcium in patients
exposed to these agents. Calcium supplementation of the
diet should be avoided or used with care.
Clodronate
Clodronate is a relatively weak bisphosphonate, but has
been shown to decrease the risk of vertebral and non-
vertebral fractures in randomised controlled studies [91,
96]. It is widely available for the treatment of neoplastic
bone disease, but licensed for use in osteoporosis in only a
few countries.
Adherence and monitoring of treatment
Adherence to treatment
When discussing adherence there is a need to define the
terminology [97], since a wide variety of definitions are
used in the literature.
1. Adherence is a general term encompassing the aspects
mentioned below.
2. Persistence describes for how long the medication is
taken. Persistence could be expressed as number of
days until drop-out or the proportion of the cohort still
on the medication after a given time since first
prescription. Non-persistence is assumed to be the
same as discontinuation if a treatment gap is longer
than a set number of days.
3. Compliance denotes the proximity to the treatment
recommendation as given in the official product
information (SPC). It is often simplified to mean the
number of doses taken divided by the number of
prescribed doses. This simplification does not include
some important aspects of compliance, such as taking
medication with food (for the oral bisphosphonates), at
the correct time of the day, too large doses to
compensate for forgotten doses, pill dumping, etc.
4. Primary non-adherence is when the patient is pre-
scribed a drug and then never fills the prescription.
Non-adherence to medical therapy is a widespread
public health problem. It is estimated that only half of the
patients comply with long-term therapy, of whom a
substantial minority do not even redeem their prescription.
Poor adherence to treatment is common in osteopenia
and osteoporosis. Overcoming non-adherence presents
particular challenges in asymptomatic bone diseases and
other chronic, asymptomatic conditions. In such settings,
the level of perceived threat to health does not motivate the
patient to adhere to therapy. In addition, risk of non-
adherence with any therapy increases with increased
duration of treatment [98].
Poor adherence to medication is associated with adverse
effects on outcomes in osteoporosis or osteopenia, and non-
adherent patients have smaller decreases in rates of bone
turnover, smaller gains in BMD and a significantly greater
risk of fracture [99].
Improving adherence to osteoporosis therapy requires
effective patient/provider communication and close
patient monitoring for the early identification of declining
adherence. Patients’ belief in a medication contributes to
better adherence and can be improved by firmly associating
treatment with expected benefits such as reduced risk of
fracture and thereby an improved quality of life. Patients
may be encouraged to adhere when presented with
measurements of biochemical markers of bone turnover or
their BMD results together with an explanation of how
these measures relate to risk reduction. Another primary
component of improving adherence is to use simplified or
user-friendly treatment programs [100].
It should be noted that inadequate adherence can also
take the form of improper drug administration, even when
doses are not missed. An example is the malabsorption of
oral bisphosphonates when taken with food. Such non-
adherence poses the potential problems of decreased drug
absorption and increased risk of adverse effects [101].
Monitoring of treatment with densitometry
The goal of drug therapy in a patient with osteoporosis is to
significantly increase bone strength, in order to decrease the
risk of fracture. In untreated men and women, BMD is one
of the major determinants of bone strength, and low BMD
is an important predictor of fracture. Whether the long-term
anti-fracture efficacy of anti-osteoporotic drugs will depend
410 Osteoporos Int (2008) 19:399–428on the extent to which treatment can increase or maintain
BMD is controversial. Meta-regressions, based on summary
statistics demonstrate a stronger correlation between the
change in BMD and fracture risk reduction than results
based on the individual patient data [102, 103].
Whereas 16% of vertebral fracture risk reduction after
treatment with alendronate was attributed to an increase in
BMD at the lumbar spine [104], larger increases in BMD at
both the spine and hip, observed with alendronate were
associated with greater reductions in the risk of non-vertebral
fractures. However, for patients treated with risedronate or
raloxifene, changes in BMD predict even more poorly the
degree of reduction in vertebral (raloxifene) or non-vertebral
(risedronate) fractures. Twelve percent and 7% of the
effects of risedronate to reduce non-vertebral fractures were
attributed to changes in the spine and femoral neck BMD
respectively [105]. For raloxifene, the percentage changes in
BMD accounted for 4% of the observed vertebral fracture
risk reduction [106].
For bone-forming agents, increases in BMD account for
approximately one-third of the vertebral fracture risk reduc-
tion with teriparatide [107]. Preliminary data suggest that a
larger proportion (up to 74%) of the anti-fracture efficacy of
strontium ranelate might be explained by changes in total hip
or femoral neck BMD [108]. Further data are needed on the
role of BMD monitoring patients treated with bone-forming
agents, but appears to be of greater value than their use with
inhibitors of bone resorption.
Monitoring of treatment with biochemical markers of bone
turnover
Several markers have been developed over the past 20 years
that reflect the overall rate of bone formation and/or bone
resorption. Most are immunoassays using antibodies that
recognise specifically a component of bone matrix (i.e. type
I collagen or non-collagenous proteins) that is released in
the bloodstream during the process of either osteoblastic
bone formation or osteoclastic resorption. Other assays
recognise enzymatic activity associated with the osteoblast
(bone alkaline phosphatase) or the osteoclast (tartrate-
resistant acid phosphatase). The most informative ones for
the investigation of osteoporosis are osteocalcin and
procollagen I N-terminal extension peptide (P1NP) for
assessing bone formation, and type I collagen – and C-
telopeptide breakdown products (especially serum CTX) to
assess bone resorption [109, 110].
Antiresorptive therapies such as calcitonin, oestrogen,
SERMs and bisphosphonates induce a significant decrease
in bone markers that return to the premenopausal range
within 3–6 months for the resorption markers and within 6–
9 months for markers of formation. The decrease in markers
of bone turnover seen with alendronate or oestrogen is
dose-related and correlates with the long-term (2–3 years)
increase in BMD at the spine and hip [111]. More
importantly, a significant association has been reported
between the short-term decrease and the absolute level of
markers of bone turnover with the use of antiresorptive
agents (raloxifene and bisphosphonates) on the one hand,
and the magnitude of the reduction of the risk of vertebral
and non-vertebral fractures on the other hand [112–114]. In
addition, a large prospective study suggests that the use of
markers of bone turnover in the monitoring of bisphos-
phonate therapy is associated with a greater persistence
with therapy than in those not monitored [115]. Thus,
measurement of markers of bone turnover after a few
months of treatment may provide useful information on
efficacy and improve persistence. During bone-forming
therapy with teriparatide, serum P1NP increases 2- to 3-fold
within 1–3 months, a change that correlates with the
subsequent increase in BMD [116, 117]. There are no data
relating changes in bone turnover induced with teriparatide
to the subsequent reduction of fracture risk. Changes in
markers of bone turnover with strontium ranelate are of
small magnitude and are unlikely to be clinically useful for
the monitoring of treatment [68].
Assessment of fracture risk
The increasing prevalence and awareness of osteoporosis,
together with the development of treatments of proven
efficacy, will increase the demand for the management of
patients with osteoporosis. This in turn will require
widespread facilities for the assessment of osteoporosis.
Measurements of bone mineral are a central component of
any provision, since osteoporosis is defined in terms of
BMD and micro-architectural deterioration of bone tissue.
Presently, there are no satisfactory clinical tools available to
assess bone quality independently of bone density, so that
for practical purposes, the assessment of osteoporosis
depends upon the measurement of skeletal mass, as
assessed by measurements of BMD [13].
The clinical significance of osteoporosis is the fractures
that arise with their attendant morbidity and mortality. For
this reason attention has focussed on the identification of
patients at high risk of fracture rather than the identification
of men and women with osteoporosis [118]. Although bone
mass is an important component of the risk of fracture,
other abnormalities occur in the skeleton that contribute to
fragility. In addition, a variety of non-skeletal factors, such
as the liability to fall and force of impact, contribute to
fracture risk. Since BMD forms but one component of
fracture risk, accurate assessment of fracture risk should
ideally take into account other readily measured indices of
fracture risk that add information to that provided by BMD.
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The use of bone mass measurements for prognosis depends
upon accuracy. Accuracy in this context is the ability of the
measurement to predict fracture. In general, all absorptio-
metric techniques have high specificity but low sensitivity,
which varies with the cut-off chosen to designate high risk.
Many cross-sectional prospective population studies indi-
cate that the risk of fracture increases by a factor of 1.5 to
3.0 for each standard deviation decrease in BMD (see
Table 3)[ 14]. The ability of BMD to predict fracture is
comparable to the use of blood pressure to predict stroke,
and significantly better than serum cholesterol to predict
myocardial infarction [13].
Despite these performance characteristics, it should be
recognised that, just because BMD is normal, there is no
guarantee that a fracture will not occur—only that the risk is
decreased. Conversely, if BMD is within the osteoporotic
range, then fractures are more likely, but not invariable. At the
age of 50 years, the proportion of women with osteoporosis
who will fracture their hip, spine or forearm or proximal
humerus in the next 10 years (i.e. positive predictive value) is
approximately 45%. The detection rate for these fractures
(sensitivity) is, however, low and 96% of fractures at the
spine, hip, forearm or proximal humerus would occur in
womenwithoutosteoporosis[119]. The low sensitivity is one
of the reasons why widespread population-based screening
with BMD is not widely recommended in women at the time
of the menopause.
Age
The performance characteristics of the test can, however, be
improved by the concurrent consideration of risk factors that
operate independently of BMD. Perhaps the best example is
age. The same T-score with the same technique at any one site
has a different significance at different ages. For any BMD,
fracture risk is much higher in the elderly than in the young
[120]. This is because age contributes to risk independently
of BMD. At the threshold for osteoporosis (T-score = −2.5
SD), the probability of hip fracture ranges from 1.4 to 10.5%
in men and women from Sweden depending on age (Table 8)
[121]. Thus, the consideration of age and BMD together
increases the range of risk that can be identified.
There are, however, a large number of additional risk
factors that provide information on fracture risk indepen-
dently of both age and BMD.
Other clinical risk factors
A large number of additional risk factors for fracture have
been identified [122–124]. For the purposes of risk
assessment, interest lies in those factors that contribute
significantly to fracture risk over and above that provided
by BMD measurements or age [125]. A caveat is that some
risk factors identify a risk that is not amenable to particular
treatments, so that the relationship between absolute
probability of fracture and reversible risk is important.
Liability to falls is an appropriate example where the risk of
fracture is high, but treatment with agents affecting bone
metabolism may arguably have little or no effect on risk.
Over the past few years a series of meta-analyses has
been undertaken to identify clinical risk factors that could
be used in case finding strategies with or without the use of
BMD. These are summarised below and their predictive
value for hip fracture risk shown in Table 9 [126].
1. Low body mass index (BMI). A low BMI is a
significant risk factor for hip fracture. Thus, the risk
is nearly two-fold increased comparing individuals with
a BMI of 25 kg/m
2 and 20 kg/m
2 (see Table 9). It is
important to note that the comparison of 25 versus
30 kg/m
2 is not associated with a halving of risk, i.e.
leanness is more of a risk factor rather than obesity
being a protective factor. It is also important to note
that the value of BMI in predicting fractures is very
much diminished when adjusted for BMD [127].
2. Many studies indicate that a history of fragility fracture
is an important risk factor for further fracture [17, 128].
Fracture risk is approximately doubled in the presence
of a prior fracture. The increase in risk is even more
marked for a vertebral fracture following a previous
spine fracture. The risks are in part independent of
BMD. In general, adjustment for BMD would decrease
the relative risk by 10–20% (see Table 3).
3. A family history of fragility fractures is a significant
risk factor that is largely independent of BMD [129]. A
family history of hip fracture is a stronger risk factor
than a family history of other osteoporotic fractures and
is independent of BMD.
Table 8 Ten-year probability of hip fracture (percentage) in Swedish
women according to age in the general population and by BMD at the
femoral neck. (Reprinted from [121], with kind permission from
Springer Science + Business Media)
Age
(years)
Population T-score =
−1
T-score ≤
−1
T-score =
−2.5
T-score ≤
−2.5
45 0.4 0.4 0.8 1.4 2.2
50 0.6 0.5 1.1 1.7 2.9
55 1.2 0.7 2.0 2.9 5.1
60 2.3 1.1 3.3 4.4 7.8
65 3.9 1.5 5.0 5.9 10.9
70 7.3 2.0 8.3 8.8 16.7
75 11.7 2.3 11.8 11.1 21.5
80 15.5 2.5 14.6 11.5 23.8
85 16.1 2.1 14.7 10.0 21.9
412 Osteoporos Int (2008) 19:399–4284. Cigarette smoking is a risk factor that is in part
dependent on BMD [130].
5. Glucocorticoids are an important cause of osteoporosis
and fractures [131]. The fracture risk conferred by the
use of glucocorticoids is, however, not solely depen-
dent upon bone loss and BMD independent risks have
been identified [132].
6. Alcohol. The relationship between alcohol intake and
fracture risk is dose-dependent. Where alcohol intake is
on average two units or less daily there is no increase in
risk. Indeed, some studies suggest that BMD and
fracture risk may be reduced. Intakes of 3 or more
units daily are associated with a dose-dependent
increase in risk [133].
7. Rheumatoidarthritis.Therearemanysecondarycausesof
osteoporosis associated with an increase in fracture risk
(e.g. inflammatory bowel disease, endocrine disorders),
butinmostinstancesitisuncertaintowhatextentthehigh
fracture risk is dependent on low BMD or other risk
factors (e.g. the use of glucocorticoids). By contrast,
rheumatoid arthritis causes a fracture risk independently
of BMD and the use of glucocorticoids [132].
Biochemical assessment of fracture risk
Bone markers are increased after the menopause, and in
several studies the rate of bone loss varies according to the
marker value [110]. Thus, a potential clinical application of
biochemical indices of skeletal metabolism is in assessing
fracture risk. Several prospective studies have shown that
the serum levels and urinary excretion of markers of bone
turnover correlate with subsequent risk of fractures in
postmenopausal women [110, 134]. Thus, women who
have marker values of bone turnover above the premeno-
pausal range (25–40% of postmenopausal women) have
been shown in several—but not all—studies to have
approximately a two-fold increased risk of vertebral and
non-vertebral fractures, including those at the hip, indepen-
dently of age and of BMD.
Case-finding
At present there is no universally accepted policy for
population screening in Europe to identify patients with
osteoporosis or those at high risk of fracture. With the
increasing development of effective agents and price
reductions, this view may change, particularly in the case
of elderly people. In the absence of such policies, patients
are identified opportunistically using a case-finding strategy
on the finding of a previous fragility fracture or the
Table 10 Clinical risk factors used for the assessment of fracture
probability
Risk factor
Age
Sex
Low body mass index
Previous fragility fracture, particularly of the hip, wrist and spine
including morphometric vertebral fracture
Parental history of hip fracture
Glucocorticoid treatment (>5 mg prednisolone daily or equivalent for
3 months or more)
Current smoking
Alcohol intake 3 or more units daily
Secondary causes of osteoporosis
Rheumatoid arthritis
Untreated hypogonadism in men and women, e.g. premature
menopause, bilateral oophorectomy or orchidectomy, anorexia
nervosa, chemotherapy for breast cancer, hypopituitarism
Inflammatory bowel disease, e.g. Crohn’s disease and ulcerative
colitis. It should be noted that the risk is in part dependent on the
use of glucocorticoids, but an independent risk remains after
adjustment for glucocorticoid exposure
Prolonged immobility, e.g. spinal cord injury, Parkinson’s disease,
stroke, muscular dystrophy, ankylosing spondylitis
Organ transplantation
Type I diabetes
Thyroid disorders, e.g. untreated hyperthyroidism, over-treated
hypothyroidism
Chronic obstructive pulmonary disease
Table 9 Risk ratio (RR) for
hip fracture and 95% confi-
dence intervals (CI) associated
with risk factors adjusted for
age, with and without adjust-
ment for BMD. (Reprinted
from [126], with kind
permission from Springer
Science + Business Media)
Without BMD With BMD
Risk indicator RR 95% CI RR 95% CI
Body mass index (20 v 25 kg/m
2) 1.95 1.71–2.22 1.42 1.23–1.65
(30 v 25 kg/m
2) 0.83 0.69–0.99 1.00 0.82–1.21
Prior fracture after 50 years 1.85 1.58–2.17 1.62 1.30–2.01
Parental history of hip fracture 2.27 1.47–33.49 2.28 1.48–3.51
Current smoking 1.84 1.52–2.22 1.60 1.27–2.02
Ever use of systemic glucocorticoids 2.31 1.67–3.20 2.25 1.60–3.15
Alcohol intake >2 units daily 1.68 1.19–2.36 1.70 1.20–2.42
Rheumatoid arthritis 1.95 1.11–3.42 1.73 0.94–3.20
Osteoporos Int (2008) 19:399–428 413presence of significant risk factors. The risk factors that are
used for clinical assessment are summarised in Table 10
[19]. Markers of bone turnover are not included since they
have not been validated in enough cohorts worldwide to be
readily incorporated into the algorithms.
Todate,treatment ofosteoporosishas largelybeendirected
at women with clinical risk factors determined by a set BMD.
The finding that the presence of clinical risk factors and age
modulaterisk(andthereforecost-effectiveness),reinforcesthe
view that treatment should be directed on the basis of fracture
probability, rather than on a single BMD threshold [18, 19,
118, 125, 135, 136]. The preferred metric is the probability
of fracture, but practising physicians are not yet familiar with
the assessment of fracture probability, although algorithms
will shortly be available to assess these [18, 19].
A possible algorithm for case-finding is shown in Fig. 3
[137]. It is based on knowledge of the interactions of the
clinical risk factors, age and BMD and is applied to the UK.
Its rationale is reviewed later (see Health economics). The
management algorithm provides for the treatment of
patients with a previous fragility fracture without the need
for a BMD test, since a prior fracture is a very strong risk
factor that is largely independent of BMD. For the other
risk factors treatment can be delivered cost-effectively in
women aged 65 years or more, but in women below this
age, further stratification of risk is indicated with a BMD
test. For women with a parental history of hip fracture,
treatment becomes worthwhile with a BMD T-score of −1
SD or less at the femoral neck or total hip. For women
taking long-term glucocorticoids, a T-score threshold of
−2.0 SD is appropriate, whereas for the weaker risk factors
(secondary causes of osteoporosis, current smoking and
alcohol consumption of 3 or more units daily), an
appropriate threshold would be a T-score of −2.5 SD. The
schema illustrates the advantage to patients in not using a
single T-score value to judge suitability for treatment as has
been widely practised in Europe. Although treatment can be
given cost-effectively in many patients without the need for
a BMD test, it is a commonly held view that treatment
should not be undertaken in women without recourse to a
BMD test except in women with prior fragility fractures.
The adoption of such a strategy would not adversely affect
estimates of cost-effectiveness, since BMD testing was
included in all scenarios. Rather, the avoidance of BMD
testing would make treatment even more cost-effective.
Whereas this schema can be justified from a health
economic perspective in the UK, other factors will
determine whether similar thresholds for age and BMD
are appropriate for individual countries.
Comparison of case-finding strategies
The utility of a bone densitometry service has been
previously evaluated for the UK following the guidelines
of the European Foundation for Osteoporosis (now the
International Osteoporosis Foundation). The use of bone
densitometry was considered to be justifiable in terms of
the cost per averted fracture and more cost-effective than
the treatment of patients with risk factors in whom BMD
was not known [30].
The effectiveness of the case-finding strategy previously
used in Europe (EUR) [30] has been compared with that
Women with CRFs
Prior fragility
fracture
Other CRFs
Age 65+ years Age < 65 years
Consider
treatment BMD test
Consider
treatment
Parental history of
Hip fracture
Treat if T-score < -1
Glucocorticoids
Treat if T-score < -2
Secondary causes of OP
Cigarette smoking
Alcohol > 3 units daily
Treat if T-score < -2 .5
Fig. 3 Management algorithm in postmenopausal women based on an health economic analysis for the UK. (Adapted from [137])
414 Osteoporos Int (2008) 19:399–428proposed in the present guideline (WHO) [138]. The
comparisons were derived from simulations based on the
data of ten prospective population-based cohorts with a
follow-up of approximately 250,000 person-years. For this
comparison, modelled on the UK, the same risk factors and
the same number of BMD tests were used in each approach.
The EUR strategy selected candidates for BMD tests on
the basis of the presence of clinical risk factors and treatment
recommended where the T-score for BMD was ≤−2.5 SD.
For the purpose of this study, the risk factors used comprised
a prior history of a fragility fracture, a BMI <19 kg/m
2,a
parental history of hip fracture, long-term use of oral
glucocorticoids, rheumatoid arthritis, current smoking and
an average intake of alcohol of 3 or more units daily as
given in the present guidelines. The number of BMD tests
modelled for both strategies was determined, therefore, by
the age-specific prevalence of the clinical risk factors.
Assuming a treatment efficacy of 35%, the numbers of hip
fractures avoided by the two strategies are shown in
Table 11 [138].
Compared with the EUR strategy, the WHO approach
identifies more patients at high risk of hip fracture and thus
makes more effective use of BMD tests. At each age, the cost
per averted hip fracture is lower with the WHO approach.
Integrating risk factors
The use of clinical risk factors in conjunction with BMD
and age improves sensitivity of fracture prediction without
adverse effects on specificity. The multiplicity of these risk
factors poses problems in the units of risk to be used. The
T-score becomes of little value in that different T-score
thresholds for treatment would be required for each
combination of risk factors. Although the use of relative
risks is feasible, the metric of risk best suited for clinicians
is the absolute risk (or probability) of fracture.
Fracture probability
The absolute risk of fracture depends upon age and life
expectancy as well as the current relative risk. In general,
the remaining lifetime risk of fracture decreases with age,
especially after the age of 70 years or so since the risk of
death with age outstrips the increasing incidence of fracture
with age. Estimates of lifetime risk are of value in
considering the burden of osteoporosis in the community,
and the societal effects of intervention strategies. For
several reasons they are less relevant for assessing risk in
individuals in whom treatment might be envisaged [119];
therefore, the IOF and the WHO recommend that risk of
fracture should be expressed as a short-term absolute risk,
i.e. probability over a 10-year interval [118]. The period of
10 years covers the likely duration of treatment and the
benefits that may continue once treatment is stopped.
The major advantage of using absolute fracture proba-
bility is that it standardises the output from the multiple
techniques and sites used for assessment and incorporates
the additional information derived from age and the clinical
risk factors. The estimated probability will of course
depend upon the performance characteristics (gradient of
risk) provided by any technique at any one site.
The general relationship between relative risk and 10-year
probability of hip fracture is shown in Table 12 [119]. For
example, a woman at the age of 60 years has on average a
10-year probability of hip fracture of 2.4%. In the presence of
a prior fragility fracture this risk is increased approximately
2-fold and the probability increases to 4.8%. The integration
of risk factors is not new and has been successfully applied in
the management of coronary heart disease [139].
Table 12 Ten-year probability of fracture in women from Sweden
according to age and the relative risk (RR) to the average population
(Reprinted from [119], with permission from Elsevier)
Age (years)
RR 50 60 70 80
(a) Hip fracture
1 0.57 2.40 7.87 18.00
2 1.14 4.75 15.1 32.0
3 1.71 7.04 21.7 42.9
4 2.27 9.27 27.7 51.6
(b) Hip, clinical spine, humeral or Colles’ fracture
1 5.8 9.6 16.1 21.5
2 11.3 18.2 29.4 37.4
3 16.5 26.0 40.0 49.2
4 21.4 33.1 49.5 58.1
Table 11 Comparison of pre-
vious guidelines with present
guidelines (Reprinted from
[138], with kind permission
from Springer Science +
Business Media)
*in women at high risk
Age (years) Number of DXA
tests/1000
Number of high
risk women
identified/1000*
Number of hip
fractures
expected*
Number of hip fractures
avoided (cost/avoided
fracture £000)
EUR WHO EUR WHO EUR WHO
50 450 26 41 <1 1 0.1 (174) 0.4 (63)
60 450 52 65 2 4 0.7 (37) 1.2 (22)
70 500 120 355 16 30 5.7 (5) 10.6 (3)
80 550 235 606 51 92 17.9 (1.8) 32.0 (1.2)
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Algorithms that integrate the weight of clinical risk factors
for fracture risk with or without information on BMD have
been developed by the WHO Collaborating Centre for
Metabolic Bone Diseases at Sheffield, UK. The FRAX™
tool http://www.shef.ac.uk/FRAX) computes the 10-year
probability of hip fracture or a major osteoporotic fracture.
A major osteoporotic fracture is a clinical spine, hip,
forearm or humerus fracture. Probabilities can be computed
for the index of European countries shown in Table 13,
categorised for different levels of risk [140]. Where a
country is not represented (because of the lack of
epidemiological data) a surrogate should be chosen.
Where computer access is limited, paper charts can be
downloaded that give fracture probabilities for each index
country http://www.shef.ac.uk/FRAX)a c c o r d i n gt ot h e
number of clinical risk factors. An example is given in
Table 14 for women aged 60 years in the UK. Thus, a
woman from the UK aged 60 years with a body mass index
(BMI) of 20 kg/m
2 with a prior forearm fracture and
ulcerative colitis (i.e. two clinical risk factors) has a 10-year
fracture probability of 15% (9–24%). The range is not a
confidence interval, but, because the weight of different risk
factors varies, it is a true range.
Measurement of BMD is indicated in individuals who
have a high fracture probability, provided that it will
influence the management decision. This is preferred to
blind treatment, because not all patients with clinical risk
factors will have low BMD. In some instances, treatment
will be justified without measurement of BMD, for
example in patients with fragility fractures and other
strong risk factors. In other instances, the low cost and
absence of side effects justify the use of some agents
without BMD measurements in populations (e.g. calcium
with vitamin D in the institutionalised elderly). In other
patients, the fracture probability may be so low that a
management decision will not be changed by information
on BMD. An example is a woman at the time of natural
menopause without symptoms and with none of the
clinical risk factors. This does not preclude the measure-
ment of BMD in people without risk factors in patients
who would take treatment if their BMD were low. The
general approach is shown in Fig. 4 [19]. The size of the
intermediate group in Fig. 4 in whom a BMD test would be
recommended will vary by region and country. In countries
with very limited or no access to central DXA, the size of
this segment will be very small. In those countries where
screening is recommended (e.g. in women at the age of
65 years or older) this segment will include the majority of
women.
The measurement of BMD provides the opportunity to
reassess fracture probability in the light of the test result
and the clinical risk factors. Probabilities can be computed
for the index European countries shown in Table 13 [19].
Where computer access is limited, FRAX™ charts can be
downloaded that give fracture probabilities for each index
country according to femoral neck BMD and the number of
clinical risk factors. An example is given in Table 15 for
women in the UK at the age of 60 years. Such a woman
Table 14 FRAX™ table for the 10-year probability (%) of a major osteoporotic fracture (clinical spine, hip, forearm or humerus fracture)
according to body mass index (BMI), the number of clinical risk factors (CRFs) for women aged 60 years in the UK. The range is not a
confidence interval but, because the weight of different risk factors varies, it is a true range. (Reprinted from [19], with permission)
Number of CRFs BMI (kg/m
2)
15 20 25 30 35 40 45
0 7.4 6.5 6.0 5.2 4.6 4.0 3.5
1 12 (8.4–16) 10 (7.2–13) 9.3 (6.5–12) 8.1 (5.6–11) 7.0 (4.9–9.2) 6.1 (4.2–8.0) 5.3 (3.7–7.0)
21 8 ( 1 1 –26) 15 (9.0–24) 14 (7.9–22) 12 (6.9–20) 11 (5.9–17) 9.2 (5.1–15) 8.1 (4.4–13)
3 27 (16–40) 23 (13–36) 20 (11–34) 18 (9.5–30) 16 (8.2–27) 14 (7.1–24) 12 (6.1–21)
4 39 (26–53) 33 (22–47) 29 (18–44) 26 (16–39) 23 (14–35) 20 (12–31) 17 (10–27)
©World Health Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, UK
Table 14 FRAX™ table for the 10-year probability (%) of a major
osteoporotic fracture (clinical spine, hip, forearm or humerus fracture)
according to body mass index (BMI), the number of clinical risk
factors (CRFs) for women aged 60 years in the UK. The range is not a
confidence interval but, because the weight of different risk factors
varies, it is a true range. (Reprinted from [19], with permission)
Table 13 Classification of European countries according to the
population risk of hip fracture (Adapted from [141])
Category of risk Index country Similar countries
Very high Sweden Denmark
Iceland
Norway
High UK Germany
Italy Finland
Germany
Greece
Hungary
Netherlands
Portugal
Switzerland
Medium France
Spain
Low Turkey
416 Osteoporos Int (2008) 19:399–428with a T-score for femoral neck BMD of −3.0 SD with
rheumatoid arthritis and taking oral glucocorticoids (i.e.
two clinical risk factors) has a 10-year fracture probability
of 25% (19–34%). As before, the range is not a confidence
interval, but, because the weight of different risk factors
varies, it is a true range. Note that a secondary cause of
osteoporosis, with the exception of rheumatoid arthritis,
does not add weight to the fracture risk assessment where
BMD is known. Thus, a woman from the UK aged 60 years
with a T-score for femoral neck BMD of −3.0 SD a prior
forearm fracture and ulcerative colitis (i.e. one relevant
clinical risk factor) has a 10-year fracture probability of
18% (15–21%). The relationship between fracture proba-
bility and intervention thresholds is reviewed later (see
Health economics).
Limitations
The assessment takes no account of dose-responses for
several risk factors. For example, two prior fractures carry a
much higher risk than a single prior fracture. Dose-
responses are also evident for glucocorticoid use. An
example is given in Fig. 5 [131]. A prior clinical vertebral
fracture carries an approximately two-fold higher risk than
other prior fractures. Since it is not possible to model all
such scenarios with the FRAX™ algorithm, these limi-
tations should temper clinical judgement.
A further limitation is that the FRAX™ algorithm uses
T-scores for femoral neck BMD. Whereas the performance
characteristics of BMD at this site are as good as or better
than other sites, the question arises whether T-scores from
other sites and technologies can be used. Unfortunately, the
T-score and Z-score vary according to the technology used
and the site measured. In the case of total hip BMD,
however, this can be used interchangeably with femoral
neck BMD in women, but not in men. Where the
performance characteristics are known (i.e. gradient of risk
or risk ratios) probabilities can be determined from tables in
development.
Investigation of patients with osteoporosis
Diagnostic work-up
The same diagnostic approach should be undertaken in all
patients with osteoporosis irrespective of the presence or
absence of fragility fractures. However, the range of clinical
and biological tests will depend on the severity of the
disease, the age at presentation and the presence or absence
of vertebral fractures. The aims of the clinical history,
physical examination and clinical tests are:
1. To exclude a disease that can mimic osteoporosis (e.g.
osteomalacia, myelomatosis)
2. To elucidate the causes of osteoporosis and contributory
factors
3. To assess the severity of osteoporosis to determine the
prognosis of the disease, i.e. the risk of subsequent
fractures
4. To select the most appropriate form of treatment
Table 15 FRAX™ table for the 10-year probability (%) of a major osteoporotic fracture (clinical spine, hip, forearm or humerus fracture)
according to BMD, the number of clinical risk factors (CRFs) for women aged 60 years in the UK. THE range is not a confidence interval, but,
because the weight of different risk factors varies, it is a true range. (Reprinted from [19] with permission)
Number of CRFs BMD T-score (femoral neck)
−4.0 −3.0 −2.0 −1.0 0 1.0
0 23 12 7.7 5.5 4.6 4.1
1 32 (29–37) 18 (15–21) 11 (8.2–14) 8.0 (5.5–11) 6.8 (4.5–9.5) 6.0 (3.9–8.4)
2 44 (38–54) 25 (19–34) 16 (10–24) 12 (6.7–18) 9.8 (5.4–16) 8.6 (4.6–14)
3 58 (48–68) 35 (25–49) 23 (14–36) 16 (8.7–28) 14 (6.9–25) 12 (5.9–22)
4 71 (59–78) 46 (35–59) 31 (22–44) 22 (14–35) 19 (11–31) 17 (9.4–28)
©World Health Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, UK
Table 15 FRAX™ table for the 10-year probability (%) of a major
osteoporotic fracture (clinical spine, hip, forearm or humerus fracture)
according to BMD, the number of clinical risk factors (CRFs) for
women aged 60 years in the UK. THE range is not a confidence
interval, but, because the weight of different risk factors varies, it is a
true range. (Reprinted from [19] with permission)
CRFs
Fracture
probability
High
Treat
Intermediate Low
BMD
Reassess
probability
High Low
Treat
Fig. 4 Algorithm for the assessment of fracture probability. (Reprinted
from [20], with permission)
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monitoring of treatment
The procedures that may be relevant to the investigation
of osteoporosis are shown in Table 16. These investigations
may be used to:
1. Establish the diagnosis of osteoporosis (e.g. DXA or X-rays
2. Establish the cause (e.g. thyroid function tests for
hyperthyroidism, and urinary free cortisol for Cushing
syndrome)
3. Establish differential diagnosis (e.g. protein electropho-
resis for myeloma, and serum calcium and alkaline
phosphatase for osteomalacia)
Investigations commonly reserved for specialist centres
include measurement of the biochemical indices of bone turn-
over, serum parathyroid hormone, serum 25-hydroxyvitamin
D, serum or urine protein electrophoresis, fasting and
24-h urinary calcium, urinary free cortisol, thyroid function
tests and transiliac bone biopsy. Free testosterone, gonadotro-
phin and prolactin measurements may be of value in men.
Assessment is guided by the clinical findings, and some
patients who apparently have primary osteoporosis, are
subsequently found to have mild hyperparathyroidism or
hyperthyroidism, systemic mastocytosis, the late appearance
of osteogenesis imperfecta or osteomalacia.
Differential diagnosis of osteoporosis
Specific underlying causes of bone loss are more commonly
found in men than in women. In a high proportion of men
presenting with symptomatic vertebral crush fractures an
underlying cause of osteoporosis is identified, such as
hypogonadism, oral steroid therapy or alcoholism. Case-
control studies have shown a significantly increased risk of
vertebral fractures with smoking, alcohol consumption and
alcoholism, oral glucocorticoid therapy, anticonvulsant treat-
ment, hypogonadism and underlying causes of osteoporosis.
For hip fractures, the risk factors in men are similar to those
found in women.
Osteomalacia and malignancy commonly induce bone loss
and fractures. Osteomalacia is characterised by a defect of
mineralisation of bone matrix most commonly attributable to
impaired intake, production or metabolism of vitamin D.
Other causes include impaired phosphate transport or the
chronic use of some drugs such as aluminium salts (and other
phosphate-binding antacids), high doses of fluoride or
etidronate, and the chronic use of anticonvulsants. In most
cases, the diagnosis of osteomalacia is suspected by the
clinical history and by abnormalities in biochemical tests such
as low values of serum and urinary calcium, serum phosphate
and 25-hydroxyvitamin D, and high values for alkaline
phosphatase and parathyroid hormone. A transiliac bone
biopsy after tetracycline labelling may be necessary to
demonstrate unequivocally a defect in mineralisation.
Diffuse osteoporosis with or without pathological fracture
is common in patients with multiple myeloma, a condition
suspected by the severity of bone pain, increased sedimen-
Table 16 Routine procedures proposed in the investigation of
osteoporosis
Procedure
Routine
History and physical examination
Blood cell count, sedimentation rate, serum calcium, albumin,
creatinine, phosphate, alkaline phosphatase and liver transaminases
Lateral radiograph of lumbar and thoracic spine
Bone densitometry (dual energy X-ray absorptiometry)
Other
X-ray—vertebral fracture assessment
Markers of bone turnover, when available
Women Men
High dose
Medium dose
Low dose
Control
Incidence (%)
<35   40      50       60     70      80    >85 <35   40      50       60     70     80    >85
Age (years)
0.8
1.2
1.4
0.4
0
0.2
0.6
1.0
Fig. 5 The effects of glucocor-
ticoid dose on the incidence of
fracture. (Reprinted from [131],
with kind permission from
Springer Science + Business
Media)
418 Osteoporos Int (2008) 19:399–428tation rate and Bence-Jones proteinuria, and identified by
marrow aspirate and serum and urine (immuno) electropho-
resis of proteins. Similarly, pathological fractures resulting
from metastatic malignancies can mimic osteoporosis and
can be excluded by clinical and radiological examination,
biological tests such as tumour markers, and scintigraphy or
other imaging techniques. Vertebral fractures in osteoporosis
should be differentiated from vertebral deformities attribut-
able to other disorders such as scoliosis, osteoarthrosis and
Scheuermann’s disease.
Health economics
There is an increasing need for management strategies to be
placed in an appropriate health economic perspective for
guideline development and for reimbursement.
Types of evaluation
A widely used measure is the “number needed to treat”
(NNT) to prevent a fracture. For example, if a treatment
reduces the incidence of vertebral fracture from 10% to 5%
during the conduct of a trial, then 5 fractures are saved for
each 100 patients treated, which gives an NNT of 20. There
are several limitations in the use of NNT. First, it does not
take into account the cost of intervention. Second, its use is
only relevant to one population setting. In the example
above, the effectiveness of the intervention is 50%. If the
same efficacy is found in other populations but at a
different absolute risk, the NNT changes. Thus, if the
background fracture risk is, say, 5% and treatment reduces
this by half, then the NNT = 40. A further feature of the use
of NNT is that it does not take into account the offset of
effect of therapeutic intervention.
In the context of treatments, the most straightforward
pharmaco-economic evaluation is cost-minimisation analysis.
This approach can be used when two strategies or interven-
tions have identical effects, for example where both agents
decrease fracture rates by a fixed percentage, and neither has
adverse effects. The advantage of one over the other will then
relate only to differences in cost. In practice, the benefits and
risks ofdifferentstrategiesare rarelyequal.Cost-effectiveness
analyses takethisintoaccount.In this approach, outcomes are
converted intoa commoncurrency. Examples include the cost
per life-year saved, and the cost per fracture averted. A
limitation of using these outcomes is that comparisons across
diseases are difficult. Difficulties also arise within the same
disease area. The cost per fracture averted has, for example, a
different significance where the outcome is a hip fracture
rather than a forearm fracture.
These considerations have led to the increasing use of cost-
utility analysis as a measure of cost-effectiveness. In the
context of evaluating treatments, this takes into account not
only fractures avoided, but also any change in morbidity and
mortality from both beneficial and unwanted effects. Quality-
adjusted life-years (QALYs) are the accepted unit of measure-
ment in health economic assessment of interventions using
cost-utility analysis. In order to estimate QALYs, each year of
life is valued according to its utility to the patient. Values range
from 0, the least desirable health state, to 1, or perfect health.
The decrement in utility associated with fractures is the
cumulative loss of utility over time. A comparable approach
favoured by WHO is the use of disability-adjusted life-years
(DALYs). This has been extensively used to characterise the
burden of disease worldwide [141].
Willingness to pay
There is at present little information as to when treatment
can be considered to be cost-effective in the majority of
countries. One method of estimating the societal value of a
QALY is based on the value of a statistical life. Using this
approach, the value of a QALY has been estimated at about
SEK 655,000 (about €71,000 – all currency conversions as
of October 2007) in Sweden [142]. Another way of
inferring threshold values is based on past reimbursement
decisions and guidelines made by national government
agencies, such as in the UK (€23,000 –34,000/QALY),
Australia (€20,000–36,000/life year gained) and New
Zealand (€7,700/QALY) [143]. Other threshold values that
can be derived from the literature vary substantially (from
€13,000 to €460,000), depending on the country, perspec-
tive, outcome measure (e.g. life-year or a QALY) and
methodology [144]. Yet another approach is to base the
threshold value on a measure of a country’s economic
performance. For example, the WHO Commission on
Macroeconomics and Health has suggested that interven-
tions with a cost-effectiveness ratio lower than 3 times the
gross domestic product (GDP) per capita for each averted
disability-adjusted life-year (DALY) could be considered
good value for money in developing countries [145].
Assuming that the value for a DALY and a QALY are
reasonably comparable, then a cost-effective threshold for
the UK would be €54,000. It is not specified in the report of
the WHO Commission what costs should be included, but
if all costs are included (all direct and indirect costs
regardless of payer), then the threshold value should be
set at a lower level when a health-care perspective (only
costs related to the health-care sector considered) is taken.
Using the 0.6 ratio for adjustment as suggested by Kanis
and Jönsson [144], the threshold values would be about
€32,000 in the UK, close to the recommendation of the
National Institute for Health and Clinical Excellence
(NICE), and about €9,000 in Turkey. Although the GDP
per capita provides an index of affordability, there is also a
Osteoporos Int (2008) 19:399–428 419marked heterogeneity in the proportion of GDP that
countries are willing to devote to health care, and in the
proportion of the population at risk of osteoporotic fracture
(i.e. elderly people). These factors will also affect what is
an acceptable price to pay, which needs to be defined on a
country by country basis [19].
Studies of intervention
There has been a rapid expansion of research on the cost-
utility of interventions in osteoporosis, which has recently
been reviewed [146, 147]. Attention was originally
focussed on hormone replacement treatment, but is now
more commonly directed at bone-specific agents. Despite
the use of different models, different settings and payer
perspectives, analyses suggest that there are cost-effective
scenarios that can be found in the context of the
management of osteoporosis for all but the most expensive
interventions illustrated below in a UK setting.
The cost-effectiveness of the base case treatment (£350)
and efficacy (35% effectiveness) is shown in Fig. 6 for
different ages and clinical scenarios [148]. As expected, cost-
effectiveness improved at any age with increasing fracture
probability, because of the higher risk of fracture and thus the
greater number of fractures avoided.
In women with a prior fragility fracture, and without
knowledge of BMD, it was cost-effective to intervene from
the age of 65 years. In women at the threshold of osteoporosis
(i.e. a T-score at the femoral neck equal to −2.5 SD and no
prior fracture), it was cost-effective to intervene from the age
of 60 years. In women at the threshold of osteoporosis with a
T-score of −2.5 SD, it was cost-effective to intervene if there
was a history of a prior fracture, irrespective ofage.In women
witha T-scoreoflessthan−2.5 SD itwas,therefore,alsocost-
effective to intervene, irrespective of the presence or absence
of a prior fragility fracture and irrespective of age. These
observations illustrate the important effect of combining
independent risk indicators.
A reference model
A reference health economic model is available for the
evaluation of intervention in osteoporosis [149]. The model,
constructed in a Swedish setting, can be used for analysing
different populations: female or male, high-risk popula-
tions, and different ages. The model produces the change in
costs and effectiveness (in terms of QALYs) for interven-
tion compared with no intervention. The model uses a
societal perspective where direct and indirect costs related
to intervention, morbidity and mortality are included. As an
option, mortality costs (costs in added life-years) may be
excluded. The model also provides an opportunity to
incorporate negative (side effects) or positive effects during
therapy. An interface version and a description of the model
are available on the internet http://www.iofbonehealth.org/
health-professionals/health-economics/cost-effectiveness-
model.html). The model permits the estimation of the cost-
effectiveness over different ranges for a selected number of
parameters (e.g. age, fracture risk, cost of intervention).
There are several reasons why a reference model isneeded.
First,itmaybeusedasacommonreferencefortheassessment
of new therapies. If every new technology is accompanied by
a new model it may be difficult to conclude whether the cost-
effectiveness results are a consequence of the model or of the
newtechnology.Second,newmodelscanbevalidatedagainst
the reference model based on a given set of data. Such a
validation provides an opportunity to discuss and compare
results and clarify the reasons for discrepancies. Third, it will
provide an opportunity to use a well-validated model to
investigate the effect of new data for a specific population
(country) or for a new technology.
Intervention thresholds
Intervention thresholds can be defined as the fracture
probability at which an intervention becomes acceptable.
Decisions about the need for treatment depend not only upon
the fracture probability, but also the efficacy, costs and side
effects of treatment and the willingness to pay. All these
differ between countries, so that intervention threshold will
differ accordingly. In Europe, intervention thresholds have
been estimated for Austria, Germany, Spain, Sweden and the
UK [148, 150–153] using a cost-effectiveness analysis to
determine the hip fracture probability at which intervention
with a bisphosphonate becomes cost-effective.
Developments in the ability to assess fracture probability
in individuals rather than in populations pose new chal-
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Fig. 6 Cost-effectiveness (£000/QALY gained) of treatment in
women aged 50–70 years, by the presence or absence of a prior
fracture and osteoporosis. (Reprinted from [148], with permission
from Elsevier). The solid horizontal line indicates the threshold for
cost-effectiveness (£30,000—approximately 43,000 Euros – currency
conversion here and elsewhere at October 2007)
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In addition, the cost of intervention has decreased with the
introduction of generic alendronate in some European
countries. These developments mean that previous esti-
mates of intervention thresholds based on cost-effectiveness
need to be revised using models that integrate the weights
of the different clinical risk factors on the risk of fracture
and death [137, 154].
Setting intervention thresholds
For the purposes of this guidance, the cost-effectiveness of a
5-year treatment with alendronate is compared with no
intervention in a UK setting by simulating costs and
outcomes in cohorts of women from the age of 50 years
with different combinations of clinical risk factors for
fracture [137]. The UK was chosen because the fracture
risk lies intermediate between the very high risks of the
Nordic countries and the lower risks of Southern Europe.
Alendronate was chosen because of the lower price of
generic formulations currently available in Europe. Since
the price of alendronate is very low in the UK and is
unlikely to be sustained in Europe, the price of alendronate
was set at 1 Euro daily. The analysis took a health-care
perspective that included only direct costs. The results are
shown as the incremental cost-effectiveness ratio (ICER),
i.e. cost/QALY gained. A threshold value of £30,000/
QALY gained was taken as being cost-effective (approxi-
mately 43,000 Euros).
Other interventions were examined in a sensitivity
analysis in women aged 70 years at the BMD threshold
for osteoporosis, at the BMD threshold for osteoporosis
with a prior fragility fracture, and in women with a prior
fragility fracture but no BMD test. The relative risks of
fracture with treatments were taken from a meta-analysis
[52]. In the case of raloxifene, an effect of the agent on
breast cancer was also incorporated (RR = 0.38; 95%
confidence interval = 0.24–0.58) [155]. For strontium
ranelate, an additional scenario was modelled that included
a post hoc analysis, accepted by the Committee of Human
Medicinal Products of the European Medicines Evaluation
Agency, showing a marked effect on hip fracture risk [74].
Oral ibandronate was also modelled, based on a study using
2.5 mg daily or an intermittent regimen of 20 mg on
alternate days for 12 doses every 3 months [58]. Other
assumptions are given elsewhere [136].
Thresholds in the UK
The cost-effectiveness of alendronate directed at women at
the threshold of osteoporosis is shown in Table 17.I n
women with osteoporosis (i.e. a femoral neck T-score equal
to −2.5 SD) the ICER was stable up to the age of 60 years
and, thereafter, decreased progressively with increasing age.
Treatment was cost-effective from the age of 60 years
assuming a willingness to pay of £30,000/QALY. Treatment
was also cost-effective at all ages in women who had
previously sustained a fragility fracture with a BMD set at
the threshold of osteoporosis. A prior fragility fracture was
a sufficiently strong risk factor that treatment was cost-
effective even in women without other risk factors in whom
BMD was not known (see Table 17). Indeed, treatment was
cost saving at the age of 80 years. With a low BMI,
treatment was cost saving from the age of 70 years.
The effect of different clinical risk factors at different
T-scores for BMD is shown in Table 18. Prior fractures and
a parental history of hip fracture were the strongest risk
factors and treatment was cost-effective across all ages with
a T-score of −1.5 SD or less. The use of glucocorticoids had
a lesser impact on cost-effectiveness, but across all ages
the ICER lay below a £30,000 threshold in women with a
T-score of −2.0 SD or below. The presence of rheumatoid
arthritis had a lesser impact on cost-effectiveness, but
across all ages the ICER lay below a £30,000 threshold of
cost-effectiveness with T-scores in the range for osteoporo-
sis. Current smoking and excessive alcohol intake were the
weakest of the clinical risk factors and, cost-effectiveness
was confined to the lower T-scores and higher ages using a
£30,000 threshold.
Inwomenwitha prior fracture,treatmentwascost-effective
at all ages after the age of 50 years, even in the absence of a
BMD test (Table 19). With a parental history of hip fracture,
treatment was cost-effective at all ages after the age of
55 years even in the absence of a BMD test. For the other
clinical risk factors the ICER lay above the cost-effectiveness
threshold at younger ages, but treatment was cost-effective
from the age of 65 years with any single risk factor.
These analyses form the basis of the recommendations
given for case-finding (see Fig. 3) in that each of the man-
Table 17 Cost-effectiveness of intervention with alendronate in
women at the threshold of osteoporosis, with or without a prior
fracture and in women with a previous fracture without BMD
a
Cost (£000)/QALY gained
Age
(years)
T-score = −2.5 T-score = −2.5 No BMD
a
No previous
fracture
+ Previous fracture + Previous fracture
50 38.9 14.3 28.6 (29.1)
55 31.7 16.9 27.0 (28.4)
60 29.2 15.7 23.2 (24.5)
65 16.1 8.1 11.5 (9.4)
70 10.9 4.7 6.3 (c.s.)
75 13.3 5.4 5.2 (c.s.)
80 13.4 4.4 c.s. (c.s.)
c.s.: cost saving
aBMI set to 26 kg/m
2 and in parentheses to 18 kg/m
2
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probability of a major osteoporotic fracture at which
intervention becomes cost-effective is approximately 7.5%.
In the presence of more than one clinical risk factor the
ICER depends on the weight of the clinical risk factor. In the
absence of information on BMD, the combination of any two
risk factors gives an ICER of less than £30,000 from the age
of 65 years. Below the age of 65 years, treatment is cost-
effective with a T-score of −2.5 SD with the weakest risk
factors. With three clinical risk factors, treatment is cost-
effective at the age of 50 years with a T-score of −2.0 SD and
at the age of 60 years with a T-score of −1.5 SD. T-score
thresholds would, however, be less stringent in the presence
of the stronger risk factors.
Other treatments
The analysis above focuses on the cost-effectiveness of
alendronate (70 mg weekly), but some other interventions
compared with no treatment were examined in sensitivity
analysis (etidronate, strontium ranelate, raloxifene, ibandro-
nate and risedronate) [137]. As expected, other treatments
were less cost-effective than alendronate (Table 20), but the
ICER fell below a £30,000/QALY threshold for all treat-
ments with the exception of intermittent ibandronate in
women with a BMD T-score of −2.5 SD and no prior
fracture. As might be expected, raloxifene became less cost-
effective when the effects on breast cancer were ignored.
Despite differences in apparent cost-effectiveness, there is,
however, no proven difference in efficacy among the majority
of treatments [156, 157] and head-to-head comparisons of
interventions with fracture outcomes are not available. For
these reasons, the value of an incremental analysis between
the individual treatments is questionable, since any resulting
hierarchy of treatments is dependent largely on price, but
otherwise meaningless in clinical terms. In addition, the large
Table 19 Cost-effectiveness of alendronate (cost £000/QALY gained)
in women with clinical risk factors and no information on BMD
a
Age
(years)
Prior
fracture
Secondary
OP
FH Smoking c.s. Alcohol
50 28.6 46.4 32.1 64.6 43.8 52.1
55 27.1 42.2 29.9 60.1 41.0 47.7
60 23.2 35.4 25.9 52.5 36.1 40.2
65 11.5 17.5 13.4 27.7 18.5 20.2
70 6.3 9.5 7.5 16.6 10.0 11.6
75 5.2 7.0 c.s. 14.8 6.3 9.8
80 c.s. c.s. c.s. 4.7 c.s. 2.2
Calculations are based on the UK (see text for details)
aBMI set at 26 kg/m
2
Table 18 Cost-effectiveness of
intervention (cost £000/
QALY gained) in women with
clinical risk factors according
to age and T-score for femoral
neck BMD. Calculations
are based on the UK (see
text for details)
Age (years) T-score (SD)
0 −1 −2 −30 −1 −2 −3
Prior fracture Family history
50 35.6 30.9 21.1 8.8 31.9 28.9 21.9 13.0
60 35.9 30.5 20.9 8.7 30.6 27.1 20.2 12.8
70 18.7 14.2 8.5 1.0 19.0 13.7 6.8 c.s.
80 44.7 27.9 12.7 c.s. 27.5 6.2 c.s. c.s.
Glucocorticoids Rheumatoid arthritis
50 44.1 38.8 27.0 12.2 51.5 44.4 30.5 14.3
60 43.5 37.5 25.9 11.1 48.9 41.5 28.3 14.8
70 21.8 16.7 9.4 c.s. 23.9 18.2 10.9 1.9
80 46.4 27.8 8.6 c.s. 51.1 30.9 13.0 c.s.
Alcohol >3 units daily Current smoking
50 56.1 47.8 32.0 14.1 74.5 63.1 40.6 16.9
60 52.9 44.4 29.6 14.8 73.5 61.5 54.0 18.9
70 26.1 19.4 11.2 1.4 37.8 28.4 16.2 c.s.
80 53.0 31.3 12.3 c.s. 75.9 44.9 16.8 c.s.
Table 20 Comparison of the cost-effectiveness (cost £000/QALY
gained) of alendronate with other interventions in women aged
70 years. (Data for treatments other than alendronate from [138], with
permission from Elsevier)
Intervention T-score = −2.5 SD No BMD
No prior
fracture
Prior
fracture
Prior
fracture
Alendronate 6,225 4,727 6,294
Etidronate 12,869 10,098 9,093
Ibandronate daily 20,956 14,617 14,694
Ibandronate intermittent 31,154 21,587 21,745
Raloxifene 11,184 10,379 10,808
Raloxifene without breast
cancer
34,011 23,544 23,755
Risedronate 18,271 12,659 13,853
Strontium ranelate 25,677 18,332 19,221
Strontium ranelate, post
hoc analysis
18,628 13,077 13,673
422 Osteoporos Int (2008) 19:399–428number of untreated patients makes “no treatment” ar e l e v a n t
comparator. Notwithstanding, alendronate can be considered
as a first-line intervention. The view arises, not because of
apparent differences in efficacy between treatments, but
because of cost. The cost-effectiveness of alendronate was
greater than that of etidronate, strontium, raloxifene, ibandr-
onate and risedronate in sensitivity analysis. Nevertheless,
cost-effective scenarios were found for treatments other than
alendronate, providing credible options for patients unable to
take alendronate. There are differences, however, in the
spectrum of proven efficacy of these alternatives across
different fracture sites that will determine their suitability in
the clinical management of individuals.
Comparison with the National Institute for Health
and Clinical Excellence
The finding of cost-effectiveness for the treatment of
osteoporosis is not surprising, given that many treatments in
osteoporosis or established osteoporosis, including alendro-
nate, have been shown to be cost-effective in a UK setting
[158–160] and that the price of alendronate has decreased in
most countries in Europe by about one-third of its former
price. These findings, however, contrast markedly with those
of the National Institute for Health and Clinical Excellence
(NICE) [161, 162], which suggest that the reduction in price,
which in the UK had decreased to less than one-third of its
former price, had little if any beneficial effect on cost-
effectiveness. The lack of impact of the price reduction of
alendronate on its cost-effectiveness in the technology
appraisal of NICE is explained in part by a number of
changes in the assumptions contained within the economic
model detailed elsewhere [163].
A major difference between the majority of studies and
that of NICE is that the latter appraisal used a 10-year rather
than a life-time horizon, contrary to its own recommenda-
tions [164]. It is unusual to provide 10-year time horizons
in chronic diseases. The 10-year horizon captures all the
costs of treatment (identification of patients and cost of
treatment), but loses a component of the benefit. For
example, an individual who dies after 9 years is dead for
life, and not for 1 year, as would be assumed in the model.
Similar considerations pertain to other consequences of
fracture. The penalties for ignoring future costs and
effectiveness have been previously shown in the context
of osteoporosis [137, 165].
Comparing osteoporosis with other chronic diseases
Information from the literature on the cost-effectiveness of
interventions in different diseases is difficult to compare,
because of differences in perspectives, data, and model
structure. Ideally, a common modelling framework should
be adopted to compare the cost-effectiveness of different
interventions within and between disease areas.
The cost-effectiveness has been estimated for a female
population aged 50–80 years with osteoporosis, hyper-
lipidaemia and hypertension alone or in combination with
risk factors such as diabetes and smoking using the same
model construct set in Sweden [166]. Patient groups were
defined by age and risk profile. At each age, four different
Table 21 Categories of risk used for health economic comparisons [166]
Disease Risk category
I II III IV
Osteoporosis BMD T-score =
−2.5 SD
BMD T-score =
−3.0 SD
BMD T-score = −2.5 SD and
prior vertebral fracture
BMD T-score = −3.0 SD and
prior vertebral fracture
Hypertension SBP = 140 SBP = 160 SBP = 140 and diabetes SBP = 160 and diabetes + smoking
Hyperlipidaemia TC 7.25 mmol/l TC 7.25 mmol/l, HDL
1.3 mmol/l
TC 7.25 mmol/l, HDL
1.3 mmol/l and diabetes
TC 7.25 mmol/l, HDL 1.3 mmol/l,
diabetes and smoking
SBP: systolic blood pressure (mm Hg); TC: total cholesterol (mmol/l); HDL: high density lipoprotein (mmol/l)
Table 22 Cost-effectiveness (Euro per QALY gained) for the treatment
ofosteoporosis,hypertensionandhyperlipidaemiaforwomenindifferent
risk groups based on a societal perspective. (Adapted from [166])
Age (years) Risk category
I II III IV
Osteoporosis
50 80,000 53,000 29,000 21,000
60 50,000 34,000 22,000 16,000
70 36,000 22,000 14,000 7,600
80 21,000 9,300 5,500 c.s.
Hypertension
50 64,000 61,000 44,000 23,000
60 46,000 37,000 33,000 21,000
70 33,000 32,000 29,000 24,000
80 37,000 35,000 34,000 31,000
Hyperlipidaemia
50 41,000 27,000 13,000 5,500
60 40,000 27,000 19,000 16,000
70 36,000 32,000 26,000 26,000
80 43,000 38,000 36,000 36,000
Osteoporos Int (2008) 19:399–428 423levels of risk were chosen for each disease. For the
osteoporosis group, patients were defined according to the
T-score for BMD (T-score −2.5 and −3.0 SD) with or
without a history of a previous fragility fracture. In the
hypertension group, women were defined according to
systolic blood pressure (140 and 160 mm Hg, equivalent to
stage I and stage II–IV hypertension), with or without type
II diabetes and smoking. In the hyperlipidaemia group,
women were categorised according to the serum level of
total cholesterol (TC) and high density lipoprotein (HDL)
cholesterol in combination with diabetes and smoking as
shown in Table 21.
The treatments comprised alendronate (70 mg weekly),
hydrochlorothiazide (25 mg daily), and simvastatin (20 mg
daily). These were chosen since they were the cheapest
within one class of first-line drugs. Intervention was
compared with no intervention. The expected risk reduc-
tions were taken from meta-analyses. A 5-year cholesterol
lowering and antihypertensive treatment was cost-effective
in all the defined patient groups (Table 22) using a value of
SEK 600,000 per QALY gained as a threshold for cost-
effectiveness (approximately 63,000 Euros), derived from
the value that the Swedish authorities put on a statistical
life. Treatment of osteoporosis was cost-effective in all
populations, except for 50-year old women without a
previous vertebral fracture, since the average fracture risks
are relatively low in this age group. However, in all other
cases the cost per QALY gained was below 63,000 Euros.
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